"molregno","standard_inchi","canonical_smiles","SAMPLE","activity_id","assay_id","doc_id","record_id","standard_relation","standard_value","standard_units","standard_flag","standard_type","activity_comment","data_validity_comment","description","assay_type","assay_test_type","assay_category","assay_organism","assay_tax_id","assay_strain","assay_tissue","assay_cell_type","assay_subcellular_fraction","tid","relationship_type","confidence_score","curated_by","src_id","src_assay_id","chembl_id","target_type","pref_name","tax_id","organism","species_group_flag","Iteration","RankSantiagoFloriane","RankSereina","cScore","rSquared","ec50","ec50_l","ec50_u","EMOLECULES_ID","supplier","CATALOG_NUMBER"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",67497,155123,15023,170427,"=",2.47,"nM",1,"IC50",,,"In vitro inhibitory activity against chloroquine-sensitive Plasmodium falciparum HB3","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL763697","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",67498,155122,15023,170427,"=",13.2,"nM",1,"IC50",,,"In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL763696","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",67499,156877,15023,170427,"=",1.92,"mg.kg-1",1,"ED50",,,"In vivo inhibition of Plasmodium falciparum infected male Swiss albino mice (Mus musculus) by oral dose","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL767360","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",67500,156876,15023,170427,"=",3.3,"mg.kg-1",1,"ED50",,,"In vivo inhibition of Plasmodium falciparum infected male Swiss albino mice (Mus musculus) by intraperitoneal dose","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL767359","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",67501,232469,15023,170427,"=",5.35,,0,"Resistance factor",,,"Resistance factor by IC50(K1)/IC50(HB3)","F",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL851634","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",551960,155965,14272,268767,"=",3.7,"nM",1,"IC50",,,"In vitro inhibition of chloroquine-sensitive Plasmodium falciparum HB3","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL762018","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",551961,155964,14272,268767,"=",27.2,"nM",1,"IC50",,,"In vitro inhibition of chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL762017","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",551962,225634,14272,268767,"=",12613.0,,0,"CAR",,,"Cellular accumulation ratio (CAR) for chloroquine sensitive HB3 strain of Plasmodium falciparum","F",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL848202","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",864034,112978,7270,54156,"=",0.077,"(mg of base) 20g-1",0,"MED",,,"Minimum effective dose which on 5th day reduced the mean infection level to one-fiftieth of the control","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Intermediate",1,,"CHEMBL723790","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",864035,228052,7270,54156,"=",15.8,,0,"Ratio",,,"Ratio of activity of quinine versus compound against Plasmodium berghei in mice","F",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL880395","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",864036,40759,7270,54156,"=",3.0,"hr",0,"Time",,,"Time taken for In vitro anti-filarial activity to immobilize breinlia booliati (adult worms)","F",,,"breinlia booliati",,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL651496","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",864037,40758,7270,54156,"=",3.0,"hr",0,"Time",,,"Time taken for In vitro anti-filarial activity to immobilize breinlia booliati (Microfilaria)","F",,,"breinlia booliati",,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL651495","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",864038,120519,7270,54156,"=",0.32,"mM kg-1",0,"LD app",,,"Lethal dose that killed mice in 48 hr","A",,,"Mus musculus",10090,,,,,50594,"N",1,"Intermediate",1,,"CHEMBL731977","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",891270,98881,8042,31012,"=",71.0,"%",0,"Reduction of live worms",,,"Antifilarial activity against Litomosoides carinii infections in the Jird at dose 25 mg/kg administered orally","F",,,"Litomosoides carinii",6299,,,,,50541,"N",1,"Expert",1,,"CHEMBL705215","ORGANISM","Litomosoides carinii",6299,"Litomosoides carinii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",891271,98875,8042,31012,"=",100.0,"%",0,"Reduction of live worms",,,"Antifilarial activity against Litomosoides carinii infections in the Jird at dose 100 mg/kg administered subcutaneously","F",,,"Litomosoides carinii",6299,,,,,50541,"N",1,"Expert",1,,"CHEMBL705209","ORGANISM","Litomosoides carinii",6299,"Litomosoides carinii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",891272,98882,8042,31012,"=",61.0,"%",0,"Reduction of live worms",,,"Antifilarial activity against Litomosoides carinii infections in the Jird at dose 25 mg/kg administered subcutaneously","F",,,"Litomosoides carinii",6299,,,,,50541,"N",1,"Intermediate",1,,"CHEMBL705843","ORGANISM","Litomosoides carinii",6299,"Litomosoides carinii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",891273,98874,8042,31012,"=",72.0,"%",0,"Reduction of live worms",,,"Antifilarial activity against Litomosoides carinii infections in the Jird at dose 100 mg/kg administered orally","F",,,"Litomosoides carinii",6299,,,,,50541,"N",1,"Expert",1,,"CHEMBL705208","ORGANISM","Litomosoides carinii",6299,"Litomosoides carinii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",906615,149386,17280,284281,"=",9.6,"nM",1,"IC50",,,"In vitro antimalarial activity against Plasmodium falciparum HB","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL758313","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",906616,149389,17280,284281,"=",15.08,"nM",1,"IC50",,,"In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL758316","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",906617,149579,17280,284281,"=",7.65,"mg.kg-1",1,"ED50",,,"In vitro antimalarial activity against Plasmodium yoelii NS in peter 4-day assay","F",,,"Plasmodium yoelii",5861,,,,,50474,"N",1,"Intermediate",1,,"CHEMBL857654","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114541,149237,16070,177468,"=",7.4,"nM",1,"IC50",,,"Inhibitory activity against chloroquine-resistant Plasmodium falciparum FcB1R","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Expert",1,,"CHEMBL761303","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114542,103050,16070,177468,"=",0.0,"%",1,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 12.5 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL714289","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114543,103059,16070,177468,"=",0.0,"%",1,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 6.3 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL714298","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114544,103055,16070,177468,"=",0.0,"%",1,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 3.1 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL714294","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114545,102871,16070,177468,,,,0,"Cytotoxicity","Toxic",,"Cytotoxicity upon MPMs (mouse peritoneal macrophages) at 12.5 uM concentration; Toxic Compound","A",,,"Mus musculus",10090,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL714953","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114546,102877,16070,177468,,,,0,"Cytotoxicity","Toxic",,"Cytotoxicity upon MPMs (mouse peritoneal macrophages) at 6.3 uM concentration; Toxic Compound","A",,,"Mus musculus",10090,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL715153","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114547,102886,16070,177468,,,,0,"NT","No toxicity",,"Cytotoxicity upon MPMs (mouse peritoneal macrophages) at 3.1 uM concentration; NT= No toxicity.","A",,,"Mus musculus",10090,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL713672","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114548,103053,16070,177468,"=",91.0,"%",0,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 25 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL714292","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114549,103057,16070,177468,"=",91.0,"%",0,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 32 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL714296","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114550,103061,16070,177468,"=",0.0,"%",1,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 8 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL714300","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114551,103047,16070,177468,"=",0.0,"%",1,"Cytotoxicity",,,"Cytotoxicity upon MRC-5 cells (diploid embryonic lung cell line) at 1 uM concentration","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Intermediate",1,,"CHEMBL716616","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114552,102875,16070,177468,,,,0,"Cytotoxicity","Toxic",,"Cytotoxicity upon MPMs (mouse peritoneal macrophages) at 32 uM concentration; Toxic Compound.","A",,,"Mus musculus",10090,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL715151","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114553,102882,16070,177468,,,,0,"NT","No toxicity",,"Cytotoxicity upon MPMs (mouse peritoneal macrophages) at 2 uM concentration; NT=No toxicity","A",,,"Mus musculus",10090,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL713668","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114554,149390,16070,177468,"=",7.3,"nM",1,"IC50",,,"Inhibitory activity against chloroquine-resistant Plasmodium falciparum THAI","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL758317","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1114555,149387,16070,177468,"=",14.5,"nM",1,"IC50",,,"Inhibitory activity against chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL758314","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1117542,126667,9357,339792,"=",5.0,,0,"Cures",,,"Number of mice surviving at 60 days postinfection when administered as a single dose of 640 mg/kg (sc) 72-h post infection","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Intermediate",1,,"CHEMBL731639","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1117543,126664,9357,339792,"=",5.0,,0,"Cures",,,"Number of mice surviving at 60 days postinfection when administered as a single dose of 320 mg/kg (sc) 72-h post infection","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Intermediate",1,,"CHEMBL732958","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1117544,126661,9357,339792,"=",5.0,,0,"Cures",,,"Number of mice surviving at 60 days postinfection when administered as a single dose of 160 mg/kg (sc) 72-h post infection","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Intermediate",1,,"CHEMBL878230","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1117545,126669,9357,339792,"=",2.0,,0,"Cures",,,"Number of mice surviving at 60 days postinfection when administered as a single dose of 80 mg/kg (sc) 72-h post infection","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Intermediate",1,,"CHEMBL731641","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1117546,137788,9357,339792,"=",11.9,"days",1,"Delta MST",,,"Change in mean survival time of trophozoite-induced Plasmodium berghei infection after 40 mg/kg subcutaneous dose","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL746449","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1117547,137786,9357,339792,"=",8.3,"days",1,"Delta MST",,,"Change in mean survival time of trophozoite-induced Plasmodium berghei infection after 20 mg/kg subcutaneous dose","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL746447","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194324,132533,8968,342806,"=",5.0,,1,"Cures",,,"Antimalarial activity, administered as a single subcutaneous dose of 640 mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Expert",1,,"CHEMBL742805","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194325,132530,8968,342806,"=",5.0,,1,"Cures",,,"Antimalarial activity as 60-day survivors in infected mice (Mus musculus) after single 320mg/kg subcutaneous dose 72 hr post infection","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL742802","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194326,132528,8968,342806,"=",5.0,,1,"Cures",,,"Antimalarial activity as 60-day survivors in Plasmodium berghei infected mice (Mus musculus) after single 160mg/kg subcutaneous dose 72 hr post infection","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL742800","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194327,132534,8968,342806,"=",2.0,,1,"Cures",,,"Antimalarial activity, administered as a single subcutaneous dose of 80 mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection","F",,,"Mus musculus",10090,,,,,50594,"N",1,"Expert",1,,"CHEMBL840400","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194328,127174,8968,342806,"=",11.9,"days",1,"Delta MST",,,"Difference in mean survival time in mice (Mus musculus) (control = 6.2 days) after single 40mg/kg subcutaneous dose 72hr post infection","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL739307","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194329,127172,8968,342806,"=",8.3,"days",1,"Delta MST",,,"Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 20 mg/kg subcutaneous dose","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL739305","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1194330,127169,8968,342806,"=",5.7,"days",1,"Delta MST",,,"Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 10 mg/kg subcutaneous dose","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Expert",1,,"CHEMBL739302","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1233460,155109,12806,42611,"=",24.0,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL763683","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1233461,155110,12806,42611,"=",20.0,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum T9-96","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL763684","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1233462,23237,12806,42611,"=",4.95,,0,"pKa",,,"pKa value of compound was evaluated","A",,,,,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL639045","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1471397,311971,21141,381010,"=",0.34,"ug.mL-1",1,"IC50",,,"Tested for growth inhibitory activity against Leishmania amazonensis promastigotes","F",,,"Leishmania amazonensis",5659,,,,,50457,"N",1,"Expert",1,,"CHEMBL834388","ORGANISM","Leishmania amazonensis",5659,"Leishmania amazonensis",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1471398,311971,21141,381010,"=",950.0,"nM",1,"IC50",,,"Tested for growth inhibitory activity against Leishmania amazonensis promastigotes","F",,,"Leishmania amazonensis",5659,,,,,50457,"N",1,"Expert",1,,"CHEMBL834388","ORGANISM","Leishmania amazonensis",5659,"Leishmania amazonensis",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1471399,301520,21141,381010,"=",,,1,"LogP",,"Potential missing data","Partition coefficient (logP)","A",,,,,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL876452","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1471400,300685,21141,381010,"=",,,0,"pKa",,"Potential missing data","pKa was determined","A",,,,,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL826124","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1794886,422247,34728,619251,"=",7.9E8,"nM",1,"IC50",,"Outside typical range","Inhibition of beta-hematin formation by BHIA assay","B",,,"Plasmodium falciparum",5833,,,,,311,"H",4,"Expert",1,,"CHEMBL855965","SINGLE PROTEIN","Histidine-rich protein",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",1819125,426926,35096,625774,"=",167000.0,"nM",1,"IC50",,"Outside typical range","Inhibition of Tween 20-induced beta-hematin formation by colorimetric assay","B",,,"Plasmodium falciparum",5833,,,,,311,"H",4,"Expert",1,,"CHEMBL909252","SINGLE PROTEIN","Histidine-rich protein",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2108541,465982,38583,694999,"=",9.7,"nM",1,"IC50",,,"Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum 3D7","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Intermediate",1,,"CHEMBL931166","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2108575,465983,38583,694999,"=",6.4,"nM",1,"IC50",,,"Antiparasitic activity against chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Intermediate",1,,"CHEMBL931167","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2108593,465984,38583,694999,"=",0.6,,0,"Ratio IC50",,,"Relative IC50 against Plasmodium falciparum K1 and 3D7","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL931168","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2108627,465985,38583,694999,,,,0,"TD50","Not Determined",,"Cytotoxicity against human KB cells by alamar blue assay","F",,,"Homo sapiens",9606,,,"KB ",,81115,"N",1,"Autocuration",1,,"CHEMBL931169","CELL-LINE","KB ",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2108657,465995,38583,694999,"=",9.5,"nM",1,"IC50",,,"Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum by [3H]hypoxanthine incorporation","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL931179","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127621,471696,39041,703554,"=",6.68,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FC27","F",,,"Plasmodium falciparum",5833,"FC27",,,,50425,"N",1,"Intermediate",1,,"CHEMBL952987","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127623,471697,39041,703554,"=",14.78,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum T996","F",,,"Plasmodium falciparum",5833,"T996",,,,50425,"N",1,"Intermediate",1,,"CHEMBL952988","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127625,471698,39041,703554,"=",18.36,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Intermediate",1,,"CHEMBL952989","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127627,471699,39041,703554,"=",17.48,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 106/1","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL952990","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127629,471700,39041,703554,"=",22.38,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Intermediate",1,,"CHEMBL952991","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127631,471701,39041,703554,"=",26.66,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum RSA11","F",,,"Plasmodium falciparum",5833,"RSA11",,,,50425,"N",1,"Intermediate",1,,"CHEMBL952992","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127633,471702,39041,703554,"=",32.71,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum 7G8-mdr7G8","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL952993","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127635,471703,39041,703554,"=",17.24,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum 34-1/E","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Intermediate",1,,"CHEMBL952994","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127662,471708,39041,703554,,,,0,"Activity","Active",,"Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min","F",,,"Plasmodium falciparum",5833,"FC27",,,,50425,"N",1,"Intermediate",1,,"CHEMBL938372","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127667,471709,39041,703554,,,,0,"Activity","Active",,"Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes after 90 min","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Intermediate",1,,"CHEMBL938373","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127673,471710,39041,703554,,,,0,"Activity","Active",,"Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Intermediate",1,,"CHEMBL938374","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2127678,471711,39041,703554,,,,0,"Activity","Active",,"Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min","F",,,"Plasmodium falciparum",5833,"RSA11",,,,50425,"N",1,"Intermediate",1,,"CHEMBL938375","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2142781,478933,39456,709847,"=",110000.0,"M-1",1,"Ka",,,"Displacement of quinaldine red from human AAG by fluorescence method","B",,,"Homo sapiens",9606,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL936359","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2142791,478937,39456,709847,"=",20000.0,"M-1",1,"Ka",,,"Binding affinity to human serum albumin on sepharose column by affinity chromatography","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,,"CHEMBL936363","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2142795,478934,39456,709847,"=",6200.0,"M",1,"Ka",,,"Binding affinity to human serum albumin by circular dichroism and UV/VIS spectroscopic method","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,,"CHEMBL936360","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156686,467220,38675,696657,"=",6.1,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum DD2","F",,,"Plasmodium falciparum",5833,"DD2",,,,50425,"N",1,"Intermediate",1,,"CHEMBL928091","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156689,467221,38675,696657,"=",10.2,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Intermediate",1,,"CHEMBL935586","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156692,467222,38675,696657,"=",4.5,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum GC03","F",,,"Plasmodium falciparum",5833,"GC03",,,,50425,"N",1,"Intermediate",1,,"CHEMBL935587","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156695,467223,38675,696657,"=",7.7,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum V1/S","F",,,"Plasmodium falciparum",5833,"V1S",,,,50425,"N",1,"Intermediate",1,,"CHEMBL935588","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156698,467224,38675,696657,"=",5.9,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum HB3","F",,,"Plasmodium falciparum",5833,"HB3",,,,50425,"N",1,"Intermediate",1,,"CHEMBL935589","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156701,467225,38675,696657,"=",4.7,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum PH3","F",,,"Plasmodium falciparum",5833,"PH3",,,,50425,"N",1,"Intermediate",1,,"CHEMBL935590","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2156704,467226,38675,696657,"=",6.4,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum TM4","F",,,"Plasmodium falciparum",5833,"TM4",,,,50425,"N",1,"Intermediate",1,,"CHEMBL935591","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220340,530503,41844,718154,"=",4.6,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum Thai after 24 hrs by semiautomated micro dilution assay","F",,,"Plasmodium falciparum",5833,"Thai",,,,50425,"N",1,"Autocuration",1,,"CHEMBL979570","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220348,530504,41844,718154,"=",4.8,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1R after 24 hrs by semiautomated micro dilution assay","F",,,"Plasmodium falciparum",5833,"FcB1R",,,,50425,"N",1,"Autocuration",1,,"CHEMBL979571","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220356,530505,41844,718154,"=",9.4,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 after 24 hrs by semiautomated micro dilution assay","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",1,,"CHEMBL979572","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220364,530506,41844,718154,"=",1276.0,,0,"Ratio CC50/IC50",,,"Selectivity index, ratio of CC50 for human MRC5 cells to IC50 for Plasmodium falciparum K1","U",,,,,,,"MRC5",,22226,"U",0,"Autocuration",1,,"CHEMBL979573","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220372,530507,41844,718154,"=",12000.0,"nM",1,"CC50",,,"Cytotoxicity against human MCR5 cells after 7 days by MTT assay","A",,,"Homo sapiens",9606,,,,,22224,"U",0,"Autocuration",1,,"CHEMBL979574","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220375,530508,41844,718154,"=",48000.0,"nM",1,"IC50",,,"Inhibition of haem polymerization after 24 hrs","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL979575","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220377,530509,41844,718154,"=",100.0,"%",0,"Activity",,,"Antimalarial activity in Plasmodium berghei ANKA 65 infected Swiss CD1 mice (Mus musculus) as reduced parasitaemia at 10 mg/kg initial oral dose and further intraperitoneal dose after 4 days","F",,,"Plasmodium berghei",5821,"ANKA 65",,,,50473,"N",1,"Autocuration",1,,"CHEMBL979576","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2220381,530512,41844,718154,,,,0,"Activity","Active",,"Antimalarial activity as increased MST in Plasmodium berghei ANKA 65 infected Swiss CD1 at 10 mg/kg initial oral followed by intraperitoneal dose after 4 days","F",,,"Plasmodium berghei",5821,"ANKA 65",,,,50473,"N",1,"Autocuration",1,,"CHEMBL979579","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273492,566882,46217,753873,"=",7.4,"mg.kg-1",1,"ED50",,,"In vivo antimalarial activity against Plasmodium yoelii NS peroral dosage","F",,,"Plasmodium yoelii",5861,"NS",,,,50474,"N",1,"Autocuration",1,,"CHEMBL958382","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273493,566884,46217,753873,"=",7.2,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum TM6","F",,,"Plasmodium falciparum",5833,"TM6",,,,50425,"N",1,"Autocuration",1,,"CHEMBL958384","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273494,566885,46217,753873,"=",5.5,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3","F",,,"Plasmodium falciparum",5833,"HB3",,,,50425,"N",1,"Autocuration",1,,"CHEMBL958385","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273501,566886,46217,753873,"=",20.0,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum K1","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,,"CHEMBL958386","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273502,566887,46217,753873,"=",15.21,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum PH3","F",,,"Plasmodium falciparum",5833,"PH3",,,,50425,"N",1,"Autocuration",1,,"CHEMBL958387","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273503,566888,46217,753873,"=",15.1,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum TM4","F",,,"Plasmodium falciparum",5833,"TM4",,,,50425,"N",1,"Autocuration",1,,"CHEMBL958388","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273504,566889,46217,753873,"=",9.5,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Dd2","F",,,"Plasmodium falciparum Dd2",57267,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL958389","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273505,567139,46217,753873,"=",8.9,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum V1/S","F",,,"Plasmodium falciparum",5833,"V1S",,,,50425,"N",1,"Autocuration",1,,"CHEMBL1031626","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273506,567140,46217,753873,"=",18.5,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum J164","F",,,"Plasmodium falciparum",5833,"J164",,,,50425,"N",1,"Autocuration",1,,"CHEMBL1031627","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273544,567144,46217,753873,"=",4.4,,0,"log Ks",,,"Binding affinity to heme assessed as binding constant for stepwise binding of 2 equivalent of drug to 1 molecule of heme in presence of 40% DMSO by UV-visible spectroscopy","B",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1031631","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273549,567145,46217,753873,"=",6.2,,0,"log Ks",,,"Binding affinity to heme assessed as binding constant for stepwise binding of 2 molecules of heme to 1 equivalent of drug in presence of 40% DMSO by UV-visible spectroscopy","B",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1031632","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2273557,567146,46217,753873,"=",0.85,"molar ratio",0,"IC50",,"Non standard unit for type","Inhibition of beta-hematin formation as molar equivalent relative to hemin causing blockade in BHIA","F",,,,,,,,,311,"H",4,"Expert",1,,"CHEMBL1031633","SINGLE PROTEIN","Histidine-rich protein",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274356,567208,46217,753873,"=",100.0,"mg kg-1",0,"Activity",,,"Toxicity in po dosed mouse assessed as drug level causing no observed adverse effects administered as single dose","A",,,"Mus musculus",10090,,,,,50594,"N",1,"Autocuration",1,,"CHEMBL1029946","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274357,567209,46217,753873,"=",100.0,"mg kg-1",0,"Activity",,,"Toxicity in po dosed mouse assessed as drug level causing no observed adverse effects administered as once daily for 4 days","A",,,"Mus musculus",10090,,,,,50594,"N",1,"Autocuration",1,,"CHEMBL1029947","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274358,567210,46217,753873,,,,0,"Activity","Toxic",,"Toxicity in po dosed mouse assessed as induction of hepatotoxicity at drug dose above no observed adverse effects level","A",,,"Mus musculus",10090,,,,,50594,"N",1,"Autocuration",1,,"CHEMBL1029948","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274359,567211,46217,753873,,,,0,"Activity","Toxic",,"Toxicity in po dosed mouse assessed as induction of hematological toxicity at drug dose above no observed adverse effects level","A",,,"Mus musculus",10090,,,,,50594,"N",1,"Autocuration",1,,"CHEMBL1029949","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274360,567212,46217,753873,"=",3.08,,1,"Log D",,,"Distribution coefficient, log D at pH 7.4","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1029950","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274361,562539,46217,753873,"=",10756.8,,0,"Ratio",,,"Vacuolar accumulation ratio in pH 5.2 digestive vacuole","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1014531","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274362,562540,46217,753873,"=",908.4,,0,"Ratio",,,"Lipid accumulation ratio in pH 5.2 digestive vacuole","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1014532","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274373,567141,46217,753873,"=",2.1,"mg.kg-1",1,"ED50",,,"Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected CD1 mice (Mus musculus) perorally dosed daily over 4 days","F",,,"Plasmodium berghei str. ANKA",5823,,,,,50473,"N",1,"Autocuration",1,,"CHEMBL1031628","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274374,567141,46217,753873,"=",3.2,"mg kg-1",0,"ED90",,,"Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected CD1 mice (Mus musculus) perorally dosed daily over 4 days","F",,,"Plasmodium berghei str. ANKA",5823,,,,,50473,"N",1,"Autocuration",1,,"CHEMBL1031628","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274389,567201,46217,753873,"=",78000.0,"nM",1,"TC50",,,"Toxicity against Wistar rat hepatocytes after 6 hrs by trypan blue exclusion method","A",,,"Rattus norvegicus",10116,"Wistar",,,,22224,"U",0,"Autocuration",1,,"CHEMBL1029113","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274390,567202,46217,753873,"=",8125.0,,0,"Ratio",,,"Therapeutic index, ratio of IC50 for Wistar rat hepatocytes to IC50 for Plasmodium falciparum HB3","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1029940","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274394,562541,46217,753873,"=",4.37,,1,"LogP",,,"Partition coefficient, log P of the compound","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1014533","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274400,567142,46217,753873,"=",2.6,"mg.kg-1",1,"ED50",,,"Antimalarial activity as reduced parasitaemia against Plasmodium yoelii 17X infected CD1 mice (Mus musculus) perorally dosed daily for 4 days","F",,,"Plasmodium yoelii",5861,"17X",,,,50474,"N",1,"Autocuration",1,,"CHEMBL1031629","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274401,567142,46217,753873,"=",3.7,"mg kg-1",0,"ED90",,,"Antimalarial activity as reduced parasitaemia against Plasmodium yoelii 17X infected CD1 mice (Mus musculus) perorally dosed daily for 4 days","F",,,"Plasmodium yoelii",5861,"17X",,,,50474,"N",1,"Autocuration",1,,"CHEMBL1031629","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274402,567143,46217,753873,">",40.0,"mg kg-1",0,"Activity",,,"Antimalarial activity as minimal concentration for parasite elimination at day 23 against Plasmodium yoelii 17X peroral inoculated CD1 mice (Mus musculus) dosed 1 hrs post infection then daily for 4 days","F",,,"Plasmodium yoelii",5861,"17X",,,,50474,"N",1,"Autocuration",1,,"CHEMBL1031630","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274403,567188,46217,753873,">",50.0,"mL.min-1.g-1",1,"CL",,,"Metabolic stability in mouse liver microsomes assessed as intrinsic clearance per gram of liver","A","In vitro",,"Mus musculus",10090,,"liver",,"microsomes",22224,"U",0,"Autocuration",1,,"CHEMBL1029100","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274404,567189,46217,753873,"=",9.9,"mL.min-1.g-1",1,"CL",,,"Metabolic stability in rat liver microsomes assessed as intrinsic clearance per gram of liver","A","In vitro",,"Rattus norvegicus",10116,,"liver",,"microsomes",102178,"S",2,"Autocuration",1,,"CHEMBL1029101","SUBCELLULAR","Liver microsomes",10116,"Rattus norvegicus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274405,567190,46217,753873,"=",12.0,"mL.min-1.g-1",1,"CL",,,"Metabolic stability in dog liver microsomes assessed as intrinsic clearance per gram of liver","A","In vitro",,"Canis lupus familiaris",9615,,"liver",,"microsomes",22224,"U",0,"Autocuration",1,,"CHEMBL1029102","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274406,567191,46217,753873,"=",29.0,"mL.min-1.g-1",1,"CL",,,"Metabolic stability in monkey liver microsomes assessed as intrinsic clearance per gram of liver","A","In vitro",,"Macaca mulatta",9544,,"liver",,"microsomes",22224,"U",0,"Autocuration",1,,"CHEMBL1029103","ADMET","ADMET",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274407,567192,46217,753873,"=",9.8,"mL.min-1.g-1",1,"CL",,,"Metabolic stability in human liver microsomes assessed as intrinsic clearance per gram of liver","A","In vitro",,"Homo sapiens",9606,,"liver",,"microsomes",102164,"S",2,"Autocuration",1,,"CHEMBL1029104","SUBCELLULAR","Liver microsomes",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274408,567193,46217,753873,"=",28000.0,"nM",1,"IC50",,,"Inhibition of human CYP3A4 using DEF substrate","A",,,"Homo sapiens",9606,,,,,17045,"D",9,"Autocuration",1,,"CHEMBL1029105","SINGLE PROTEIN","Cytochrome P450 3A4",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274409,567194,46217,753873,">",100000.0,"nM",1,"IC50",,,"Inhibition of human CYP3A4 using PPR substrate","A",,,"Homo sapiens",9606,,,,,17045,"D",9,"Autocuration",1,,"CHEMBL1029106","SINGLE PROTEIN","Cytochrome P450 3A4",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274410,567196,46217,753873,"=",15000.0,"nM",1,"IC50",,,"Inhibition of human CYP1A2","A",,,"Homo sapiens",9606,,,,,12594,"D",9,"Autocuration",1,,"CHEMBL1029108","SINGLE PROTEIN","Cytochrome P450 1A2",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274411,567197,46217,753873,"=",6100.0,"nM",1,"IC50",,,"Inhibition of human CYP2D6","A",,,"Homo sapiens",9606,,,,,11365,"D",9,"Autocuration",1,,"CHEMBL1029109","SINGLE PROTEIN","Cytochrome P450 2D6",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274412,567198,46217,753873,"=",2700.0,"nM",1,"IC50",,,"Inhibition of human CYP2C8","A",,,"Homo sapiens",9606,,,,,10163,"D",9,"Autocuration",1,,"CHEMBL1029110","SINGLE PROTEIN","Cytochrome P450 2C8",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274413,567199,46217,753873,"=",62000.0,"nM",1,"IC50",,,"Inhibition of human CYP2C9","A",,,"Homo sapiens",9606,,,,,12911,"D",9,"Autocuration",1,,"CHEMBL1029111","SINGLE PROTEIN","Cytochrome P450 2C9",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274414,567200,46217,753873,"=",85000.0,"nM",1,"IC50",,,"Inhibition of human CYP2C19","A",,,"Homo sapiens",9606,,,,,12912,"D",9,"Autocuration",1,,"CHEMBL1029112","SINGLE PROTEIN","Cytochrome P450 2C19",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2274415,567207,46217,753873,">",500.0,"mg kg-1",0,"Activity",,,"Toxicity in po dosed mouse assessed as maximal nonlethal dose administered as single dose","A",,,"Mus musculus",10090,,,,,50594,"N",1,"Autocuration",1,,"CHEMBL1029945","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2357240,552333,42108,767252,"=",60.0,"%",0,"Activity",,,"Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control","B",,,"Homo sapiens",9606,,,,,101311,"D",9,"Autocuration",1,,"CHEMBL1006005","SINGLE PROTEIN","Canalicular multispecific organic anion transporter 1",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395248,494886,45429,728912,"=",11.2,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 in human erythrocytes after 48 hrs by [3H]hypoxanthine uptake","F",,,"Plasmodium falciparum 3D7",36329,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL949436","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395253,494887,45429,728912,"=",9.6,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3 in human erythrocytes after 48 hrs by [3H]hypoxanthine uptake","F",,,"Plasmodium falciparum HB3",137071,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL949437","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395258,494888,45429,728912,"=",15.5,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 in human erythrocytes after 48 hrs by [3H]hypoxanthine uptake","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,,"CHEMBL949438","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395262,494889,45429,728912,"=",2.1,"mg.kg-1",1,"ED50",,,"Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected CD1 mice (Mus musculus) after 4 days","F",,,"Plasmodium berghei str. ANKA",5823,,,,,50473,"N",1,"Autocuration",1,,"CHEMBL1004632","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395266,494889,45429,728912,"=",3.2,"mg kg-1",0,"ED90",,,"Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected CD1 mice (Mus musculus) after 4 days","F",,,"Plasmodium berghei str. ANKA",5823,,,,,50473,"N",1,"Autocuration",1,,"CHEMBL1004632","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395271,494890,45429,728912,"=",2.6,"mg.kg-1",1,"ED50",,,"Antimalarial activity as reduced parasitaemia against Plasmodium yoelii 17X infected CD1 mice (Mus musculus) after 4 days","F",,,"Plasmodium yoelii",5861,"17X",,,,50474,"N",1,"Autocuration",1,,"CHEMBL1004633","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395274,494890,45429,728912,"=",3.7,"mg kg-1",0,"ED90",,,"Antimalarial activity as reduced parasitaemia against Plasmodium yoelii 17X infected CD1 mice (Mus musculus) after 4 days","F",,,"Plasmodium yoelii",5861,"17X",,,,50474,"N",1,"Autocuration",1,,"CHEMBL1004633","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395277,494891,45429,728912,">",40.0,"mg kg-1",0,"Activity",,,"Antimalarial activity as ED100 in peripheral blood against Plasmodium yoelii 17X infected CD1 mice (Mus musculus) after 4 days","F",,,"Plasmodium yoelii",5861,"17X",,,,50474,"N",1,"Autocuration",1,,"CHEMBL1004634","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395280,494893,45429,728912,"=",4.4,,0,"Activity",,,"Binding affinity to heme in DMSO assessed as equilibrium constant by UV-visible spectrophotometry","B",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1004636","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395317,494885,45429,728912,"=",28000.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate","A",,,"Homo sapiens",9606,,,,,17045,"D",9,"Autocuration",1,,"CHEMBL949435","SINGLE PROTEIN","Cytochrome P450 3A4",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395322,494884,45429,728912,">",100000.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate","A",,,"Homo sapiens",9606,,,,,17045,"D",9,"Autocuration",1,,"CHEMBL949434","SINGLE PROTEIN","Cytochrome P450 3A4",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395327,494883,45429,728912,"=",15000.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP1A2","A",,,"Homo sapiens",9606,,,,,12594,"D",9,"Autocuration",1,,"CHEMBL949433","SINGLE PROTEIN","Cytochrome P450 1A2",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395332,494881,45429,728912,"=",2700.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP2C8","A",,,"Homo sapiens",9606,,,,,10163,"D",9,"Autocuration",1,,"CHEMBL949431","SINGLE PROTEIN","Cytochrome P450 2C8",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395337,494882,45429,728912,"=",62000.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP2C9","A",,,"Homo sapiens",9606,,,,,12911,"D",9,"Autocuration",1,,"CHEMBL949432","SINGLE PROTEIN","Cytochrome P450 2C9",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395342,494880,45429,728912,">=",85000.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP2C19","A",,,"Homo sapiens",9606,,,,,12912,"D",9,"Autocuration",1,,"CHEMBL949430","SINGLE PROTEIN","Cytochrome P450 2C19",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395347,494879,45429,728912,"=",6100.0,"nM",1,"IC50",,,"Inhibition of human recombinant CYP2D6","A",,,"Homo sapiens",9606,,,,,11365,"D",9,"Autocuration",1,,"CHEMBL949429","SINGLE PROTEIN","Cytochrome P450 2D6",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2395353,494878,45429,728912,"=",2400.0,"nM",1,"IC50",,,"Inhibition of human cloned ERG","B",,,"Homo sapiens",9606,,,,,165,"D",9,"Autocuration",1,,"CHEMBL949428","SINGLE PROTEIN","HERG",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2486433,535800,44610,772179,"=",10.0,"nM",0,"Activity",,,"Inhibition of histamine N-methyl-transferase","B",,,,,,,,,11327,"H",8,"Intermediate",1,,"CHEMBL991565","SINGLE PROTEIN","Histamine N-methyltransferase",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2487328,515008,45486,728641,"=",4.6,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum THAI/Thailand as [3H]hypoxanthine uptake after 24 hrs by semi-automated micro dilution","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL979954","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2487348,515009,45486,728641,"=",4.8,"nM",1,"IC50",,,"Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcB1R/Colombia by [3H]hypoxanthine uptake","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL979955","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2503376,515010,45486,728641,"=",9.4,"nM",1,"IC50",,,"Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum K1/Thailand by [3H]hypoxanthine uptake","F",,,"Plasmodium falciparum",5833,"K1/Thailand",,,,50425,"N",1,"Autocuration",1,,"CHEMBL979956","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2503396,515011,45486,728641,"=",2500.0,,0,"Ratio CC50/IC50",,,"Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for chloroquine-resistant Plasmodium falciparum FcB1R/Colombia","U",,,,,,,"MRC5",,22226,"U",0,"Autocuration",1,,"CHEMBL980822","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2503427,515012,45486,728641,"=",12000.0,"nM",1,"CC50",,,"Cytotoxicity against human MRC5 cells after 7 days by MTT assay","A",,,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Autocuration",1,,"CHEMBL980823","CELL-LINE","MRC5",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2503447,515013,45486,728641,"=",100.0,"%",0,"Activity",,,"Antimalarial activity as reduced parasitaemia in Plasmodium berghei ANKA 65 infected Swiss CD1 mice (Mus musculus) at 10 mg/kg/day peroral dose then intraperitoneal dose for 4 days","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Autocuration",1,,"CHEMBL980824","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2503449,515014,45486,728641,,,,0,"Activity","Active",,"Antimalarial activity as increased mean survival time in Plasmodium berghei ANKA 65 infected Swiss CD1 mice (Mus musculus) at 10 mg/kg peroral dose day 1 with intraperitoneal dose over 4 days","F",,,"Plasmodium berghei",5821,,,,,50473,"N",1,"Autocuration",1,,"CHEMBL980825","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2503461,515017,45486,728641,,,,0,"Activity","Non-toxic",,"Toxicity in Plasmodium berghei ANKA 65 infected Swiss CD1 mice (Mus musculus)","A",,,"Mus musculus",10090,"Swiss CD1",,,,50594,"N",1,"Autocuration",1,,"CHEMBL980828","ORGANISM","Mus musculus",10090,"Mus musculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2610551,541173,45945,805531,"=",100.0,"ug.mL-1",1,"MIC",,,"Antitubercular activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay","F",,,"Mycobacterium tuberculosis H37Rv",83332,,,,,50309,"N",1,"Autocuration",1,,"CHEMBL1031572","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2721854,585928,48185,829662,"=",14.5,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,,"CHEMBL1056783","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2721969,585942,48185,829662,"=",7.4,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1","F",,,"Plasmodium falciparum",5833,"FcB1",,,,50425,"N",1,"Autocuration",1,,"CHEMBL1056797","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2721975,585943,48185,829662,"=",7.3,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum THAI","F",,,"Plasmodium falciparum",5833,"THAI",,,,50425,"N",1,"Autocuration",1,,"CHEMBL1056798","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2949772,590761,48495,851595,"=",1400.0,"nM",1,"IC50",,,"Antileishmanial activity against Leishmania donovani MHOM/ET/ 67/HU3 amastigote infected in CD1 mouse peritoneal exudate macrophages assessed as parasite growth inhibition after 5 days by Giemsa staining","F",,,"Leishmania donovani",5661,"MHOM/ET/ 67/HU3",,,,50459,"N",1,"Autocuration",1,,"CHEMBL1037599","ORGANISM","Leishmania donovani",5661,"Leishmania donovani",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2949795,590763,48495,851595,"=",2.15,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-susceptible Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 48 hrs by [3H]hypoxanthine reuptake assay","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1037601","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2949817,590764,48495,851595,"=",8.61,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of parasite growth after 48 hrs by [3H]hypoxanthine reuptake assay","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,,"CHEMBL1037602","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",2949840,590765,48495,851595,"=",90000.0,"nM",1,"IC50",,,"Cytotoxicity against human KB cells after 72 hrs by Alamar blue assay","A",,,"Homo sapiens",9606,,,"KB ",,81115,"N",1,"Autocuration",1,,"CHEMBL1037603","CELL-LINE","KB ",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3026583,600886,49165,867894,"=",13.04,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3027430,600885,49165,867894,"=",10.29,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3041971,600888,49165,867894,"=",2.59,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3044386,600887,49165,867894,">",100000.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3047286,600890,49166,870403,,26.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3048407,600891,49166,870403,,44.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum 3D7","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730081","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3048579,600892,49166,870403,,42.6,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730641","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3048751,600893,49166,870403,,45.0,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum V1/S","F",,,"Plasmodium falciparum",5833,"V1/S",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730642","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3048923,600894,49166,870403,">",22050.1,"nM",1,"EC50",,,"ST_JUDE: Growth inhibition of to Toxoplasma gondii, in human U-2OS cells, as measured by luciferase.","F",,,"Toxoplasma gondii",383379,"RH",,,,50472,"N",1,"Autocuration",4,,"CHEMBL730643","ORGANISM","Toxoplasma gondii",5811,"Toxoplasma gondii",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3049095,600895,49166,870403,">",38587.7,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of Trypanosoma brucei","F",,,"Trypanosoma brucei",5702,"3D7",,,,50418,"N",1,"Autocuration",4,,"CHEMBL730920","ORGANISM","Trypanosoma brucei",5691,"Trypanosoma brucei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3049245,600898,49166,870403,">",40241.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial hepatocellular carcinoma cells (HepG2)","A",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",4,,"CHEMBL1038864","CELL-LINE","HepG2",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3049417,600899,49166,870403,">",40241.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial embryonic kidney cells (HEK293)","A",,,"Homo sapiens",9606,,,"HEK293",,80936,"N",1,"Autocuration",4,,"CHEMBL1038865","CELL-LINE","HEK293",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3049589,600900,49166,870403,">",40241.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human Burkitt''s lymphoma lymphoblast cells (Raji)","A",,,"Homo sapiens",9606,,,"Raji",,80414,"N",1,"Autocuration",4,,"CHEMBL1038866","CELL-LINE","Raji",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3049734,600903,49166,870403,,32.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum SB-A6","F",,,"Plasmodium falciparum",5833,"SB-A6",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038869","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3049906,600904,49166,870403,,49.9,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum D10 transfected with yeast DHOD","F",,,"Plasmodium falciparum",5833,"D10",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038870","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3050004,600896,49166,870403,">",17226.7,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using Alamar Blue to measure viability of Leishmania major","F",,,"Leishmania major",5664,,,,,50460,"N",1,"Autocuration",4,,"CHEMBL1038862","ORGANISM","Leishmania major",5664,"Leishmania major",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3050176,600897,49166,870403,">",40241.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human forskin fibroblast cells (BJ)","A",,,"Homo sapiens",9606,,,"BJ",,80704,"N",1,"Autocuration",4,,"CHEMBL1038863","CELL-LINE","BJ",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3050503,600901,49166,870403,,74.4,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum Dd2","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038867","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3050675,600902,49166,870403,,12.0,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum W2","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038868","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3050777,600889,49166,870403,,28.6,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3270791,628796,50938,907036,"=",0.6,,1,"IC50",,,"Inhibition of beta-hematin formation assessed as drug-hematin ratio for 50% inhibition after 60 mins by colorimetric analysis","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1111877","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3278879,629651,51054,912519,"<",250.0,"nM",1,"IC50",,,"Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in human erythrocytes after 72 hrs by spectrophotometry based Malstat method","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,,"CHEMBL1120862","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3335087,636762,51449,919851,"=",18.6,"%",1,"Inhibition",,,"Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay","B",,,"Oryctolagus cuniculus",9986,,,,,103445,"D",9,"Intermediate",1,,"CHEMBL1167051","SINGLE PROTEIN","Cholesteryl ester transfer protein",9986,"Oryctolagus cuniculus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385217,648023,52096,930141,"=",0.0052,"ug.mL-1",1,"Cmax",,,"Cmax in Ugandan children patient with uncomplicated malaria at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220178","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385218,648022,52096,930141,"=",28.9,"ng.hr/ml",1,"AUC",,,"AUC (0-8 hrs) in Ugandan children patient with uncomplicated malaria at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220051","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385219,648021,52096,930141,"=",39.3,"ng.hr/ml",1,"AUC",,,"AUC (0-infinity) in Ugandan children patient with uncomplicated malaria at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220050","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385220,648020,52096,930141,"=",3.3,"hr",1,"T1/2",,,"Half life in Ugandan children patient with uncomplicated malaria at 10 mg/kg,perorally qd on first 2 days and then 5 mg/kg,perorally on third day co-administered with artesunate at 4 mg/kg,perorally bid for 3 days","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220049","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385221,648019,52096,930141,"=",0.235,"ug.mL-1",1,"Cmax",,,"Cmax in Ugandan children patient with uncomplicated malaria assessed as desethylamodiaquine level at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220048","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385222,648018,52096,930141,"=",11242.0,"ng.hr/ml",1,"AUC",,,"AUC (0-120 hrs) in Ugandan children patient with uncomplicated malaria assessed as desethylamodiaquine level at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220047","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385223,648017,52096,930141,"=",14770.0,"ng.hr/ml",1,"AUC",,,"AUC (0-infinity) in Ugandan children patient with uncomplicated malaria assessed as desethylamodiaquine level at 10 mg/kg, perorally qd on first 2 days and then 5 mg/kg, perorally on third day co-administered with artesunate at 4 mg/kg, perorally bid for 3 days","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220046","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385224,648034,52096,930141,"=",60.0,"hr",1,"T1/2",,,"Half life in Ugandan children patient with uncomplicated malaria assessed as desethylamodiaquine level at 10 mg/kg,perorallyqd on first 2 days and then 5 mg/kg,perorallyon third day co-administered with artesunate at 4 mg/kg,perorallybid for 3 days","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220189","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385229,648015,52096,930141,"=",154.0,"ng.hr/ml",1,"AUC",,,"AUC (0-infinity) in healthy human adult at 600 mg administered as single dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220044","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385230,648036,52096,930141,"=",8437.0,"ng.hr/ml",1,"AUC",,,"AUC (0-infinity) in healthy human adult assessed as desethylamodiaquine level at 600 mg administered as single dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220191","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385231,648037,52096,930141,"=",149.0,"ng/ml",1,"AUC",,,"AUC in Gabonian malarial children aged 6 months to 10 years assessed as desethylamodiaquine level at 30 mg/kg measured on third day post dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220192","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3385232,648038,52096,930141,"=",62.0,"ng/ml",1,"AUC",,,"AUC in Nigerian human adult malaria patient assessed as desethylamodiaquine level at 25 mg/kg measured on third day post dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1220193","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3390379,646859,52157,929766,"=",15000.0,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium falciparum","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1217000","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455045,659106,52669,952271,"=",26.4,"%",1,"Activity",,,"Toxicity in children with malaria under 2 years of age assessed as incidence of vomiting administered with 250 mg sulfalene/12.5 mg pyrimethamine on first day followed by compound treatment at <=15 mg/kg/day,perorally","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246880","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455046,659107,52669,952271,"=",26.4,"%",1,"Activity",,,"Toxicity in children with malaria under 2 years of age assessed as incidence of fever administered with 250 mg sulfalene/12.5 mg pyrimethamine on first day followed by compound treatment at <=15 mg/kg/day,perorally","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246881","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455047,659108,52669,952271,"=",1.9,"%",1,"Activity",,,"Toxicity in children with malaria under 2 years of age assessed as incidence of rashes administered with 250 mg sulfalene/12.5 mg pyrimethamine on first day followed by compound treatment at <=15 mg/kg/day,perorally","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246882","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455048,659109,52669,952271,"=",1.9,"%",1,"Activity",,,"Toxicity in children with malaria under 2 years of age assessed as incidence of itching administered with 250 mg sulfalene/12.5 mg pyrimethamine on first day followed by compound treatment at <=15 mg/kg/day,perorally","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246883","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455049,659110,52669,952271,"=",9.6,"%",1,"Activity",,,"Toxicity in children with malaria under 2 years of age assessed as incidence of headache administered with 250 mg sulfalene/12.5 mg pyrimethamine on first day followed by compound treatment at <=15 mg/kg/day,perorally","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246884","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455050,659111,52669,952271,"=",41.3,"%",1,"Activity",,,"Toxicity in children with malaria over 2 years of age assessed as incidence of vomiting at >=15 mg/kg/day, perorally co-treated with 500 mg sulfalene/25 mg pyrimethamine","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246885","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455051,659112,52669,952271,"=",29.8,"%",1,"Activity",,,"Toxicity in children with malaria over 2 years of age assessed as incidence of fever at >=15 mg/kg/day, perorally co-treated with 500 mg sulfalene/25 mg pyrimethamine","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246886","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455052,659113,52669,952271,"=",1.9,"%",1,"Activity",,,"Toxicity in children with malaria over 2 years of age assessed as incidence of rashes at >=15 mg/kg/day, perorally co-treated with 500 mg sulfalene/25 mg pyrimethamine","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246887","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455053,659114,52669,952271,"=",3.8,"%",1,"Activity",,,"Toxicity in children with malaria over 2 years of age assessed as incidence of itching at >=15 mg/kg/day, perorally co-treated with 500 mg sulfalene/25 mg pyrimethamine","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246888","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455054,659115,52669,952271,"=",5.8,"%",1,"Activity",,,"Toxicity in children with malaria over 2 years of age assessed as incidence of headache at >=15 mg/kg/day, perorally co-treated with 500 mg sulfalene/25 mg pyrimethamine","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246889","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455055,659116,52669,952271,"=",7.0,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of vomiting at <15 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246890","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455056,659117,52669,952271,"=",6.3,"%",1,"Activity",,,"Toxicity in children with malaria assessed as febrile incidence at <15 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246891","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455057,659118,52669,952271,"=",0.8,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of rashes at <15 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246892","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455058,659119,52669,952271,"=",9.2,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of vomiting at 15-17 mg/kg/day, perorally and cotreated with Sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246893","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455059,659120,52669,952271,"=",10.7,"%",1,"Activity",,,"Toxicity in children with malaria assessed as febrile incidence at 15-17 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246894","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455060,659121,52669,952271,"=",0.0,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of rashes at 15-17 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246895","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455061,659122,52669,952271,"=",15.3,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of vomiting at 17-19 mg/kg/day, perorally and cotreated with Sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246896","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455062,659123,52669,952271,"=",9.9,"%",1,"Activity",,,"Toxicity in children with malaria assessed as febrile incidence at 17-19 mg/kg/day, perorally and cotreated with Sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246897","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455063,659124,52669,952271,"=",0.8,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of rashes at 17-19 mg/kg/day, perorally and cotreated with Sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246898","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455064,659125,52669,952271,"=",16.3,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of vomiting at >19 mg/kg/day, perorally and cotreated with Sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246899","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455065,659126,52669,952271,"=",21.7,"%",1,"Activity",,,"Toxicity in children with malaria assessed as febrile incidence at >19 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246900","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3455066,659127,52669,952271,"=",2.2,"%",1,"Activity",,,"Toxicity in children with malaria assessed as incidence of rashes at >19 mg/kg/day, perorally and co-treated with sulfadoxine and pyrimethamine during intermittent preventive treatment to prevent malaria in children regimen","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1246901","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3468641,663634,52921,956256,"=",0.57,"ug.mL-1",1,"Solubility",,,"Intrinsic solubility of the compound in water","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1251387","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3475981,667843,53279,959974,,,,1,"Inhibition","Not Active",,"Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs in presence of 40 uM protease inhibitor ALLN","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1263481","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3475985,667842,53279,959974,,,,1,"Inhibition","Not Active",,"Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1263480","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3475986,667844,53279,959974,,,,1,"Inhibition","Not Active",,"Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs in presence of 40 uM protease inhibitor E64","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1263482","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3475999,667845,53279,959974,,,,1,"Inhibition","Not Active",,"Antimalarial activity against schizont-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as inhibition of horseradish peroxidase(HRP) uptake after 10 hrs by colorimetric peroxidase assay","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1263483","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3476004,667847,53279,959974,,,,1,"Inhibition","Active",,"Antimalarial activity against Plasmodium falciparum 3D7 infected in erythrocyte assessed as increase in vesicle content after 8 hrs by immunofluorescence microscopy","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1263485","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494164,667063,53212,960368,"=",16.5,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262957","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494170,667064,53212,960368,"=",7.85,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262958","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494176,667065,53212,960368,"=",18.9,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262959","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494182,667066,53212,960368,"=",23.4,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262960","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494188,667059,53212,960368,"=",15.2,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium falciparum at the ring stage by microscopy","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1262953","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494191,667060,53212,960368,"=",8.2,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium falciparum trophozoites by microscopy treated during ring stage","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1262954","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494194,667061,53212,960368,"=",10.0,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax at the ring stage by microscopy","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262955","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494197,667062,53212,960368,"=",24.2,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax at the trophozoites by microscopy treated during ring stage","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262956","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",3494204,667058,53212,960368,"=",22.1,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium vivax trophozoites by microscopy","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1262952","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",4922427,688609,51887,1250878,"=",17782.8,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen.   (Class of assay: confirmatory) [Related pubchem assays: 1473 , 1466 ]","F",,"confirmatory","Homo sapiens",9606,,,,,10977,"D",9,"Autocuration",7,"2100","CHEMBL1614076","SINGLE PROTEIN","Lysosomal alpha-glucosidase",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5083733,688944,54167,1311761,,,,1,"Phospholipidosis","Active",,"Phospholipidosis-positive literature compound observed in human","A",,,"Homo sapiens",9606,,,,,103779,"N",1,"Autocuration",1,,"CHEMBL1615362","PHENOTYPE","Phospholipidosis",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5143638,707351,54933,1326391,"=",67000.0,"nM",1,"IC50",,,"Inhibition of heme crystallization by cell-free heme crystallization screen assay","B",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1667136","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5143641,707352,54933,1326391,"=",1.45,"equiv",1,"IC50",,"Non standard unit for type","Inhibition of heme crystallization by hemichrome inhibition of beta-hematin assay","U",,,,,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1667137","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5143644,707353,54933,1326391,"=",6.8,"nM",1,"IC50",,,"Antimicrobial activity against Plasmodium falciparum 3D7 by DAPI growth inhibition assay","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1667138","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144418,704484,54836,1325656,"=",4.6,"%",1,"Activity",,,"Toxicity in patient infected with chloroquine-resistant Plasmodium vivax assessed as occurrence of vomitting at total dose of 30 mg/kg administered as three daily doses measured 30 minutes post dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1661800","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144419,704485,54836,1325656,"=",52.0,"%",1,"Activity",,,"Antimalarial activity against chloroquine-resistant Plasmodium vivax infected in human assessed as clearance of peripheral parasitemia at total dose of 30 mg/kg administered as three daily doses measured within 24 hrs post dose","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1661801","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144420,704486,54836,1325656,"=",91.0,"%",1,"Activity",,,"Antimalarial activity against chloroquine-resistant Plasmodium vivax infected in human assessed as clearance of peripheral parasitemia at total dose of 30 mg/kg administered as three daily doses measured 48 hrs post dose","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1661802","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144421,704487,54836,1325656,"=",30.0,"%",1,"Activity",,,"Toxicity in patient infected with chloroquine-resistant Plasmodium vivax assessed as occurrence of anemia at total dose of 30 mg/kg administered as three daily doses measured 7 days post dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1661803","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144422,704488,54836,1325656,,,,1,"Activity","Non-toxic",,"Toxicity in patient infected with chloroquine-resistant Plasmodium vivax assessed as occurrence of anemia at total dose of 30 mg/kg administered as three daily doses measured 24 days post dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1661804","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144423,704489,54836,1325656,"=",22.8,"%",1,"Activity",,,"Antimalarial activity against chloroquine-Resistant Plasmodium vivax infected in human assessed as parasite recurrence rate at total dose of 30 mg/kg administered as three daily doses measured on day 28 post dose","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1661805","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144424,704490,54836,1325656,"=",11.3,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1661806","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5144425,704491,54836,1325656,"=",4.5,"%",1,"Activity",,,"Toxicity in human infected with chloroquine-Resistant Plasmodium vivax assessed as occurrence of nausea at total dose of 30 mg/kg administered as three daily doses","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1661807","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5152173,710638,54962,1326656,"=",8.0,"nM",1,"IC50",,,"Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay","F",,,"Plasmodium falciparum VS/1",478864,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1654415","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5158104,702360,54823,1325349,"=",0.00119,"ug.mL-1",1,"Cmax",,,"Cmax in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1656401","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5158105,702361,54823,1325349,"=",47.9,"hr",1,"Tmax",,,"Tmax in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1656402","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5158106,702362,54823,1325349,"=",2.0,"hr",1,"T1/2",,,"Primary phase half life in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1656403","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5158107,702363,54823,1325349,"=",104.0,"hr",1,"T1/2",,,"Terminal half life in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose","A","In vivo",,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1656404","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5158108,702364,54823,1325349,"=",38516.0,"hr.ng/ml",1,"AUC",,,"AUC in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose","A",,,"Homo sapiens",9606,,,,,50587,"N",1,"Autocuration",1,,"CHEMBL1656405","ORGANISM","Homo sapiens",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215040,725111,55592,1332752,"=",8.1,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1675999","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215041,725112,55592,1332752,"=",12.6,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1676000","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215042,725113,55592,1332752,"=",16.5,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium vivax at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1676001","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215043,725114,55592,1332752,"=",25.2,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium vivax trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1676002","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215044,725115,55592,1332752,"=",5.7,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1676003","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215045,725116,55592,1332752,"=",14.0,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium vivax infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1676004","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5215046,725117,55592,1332752,"=",12.0,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium vivax with >50% parasites at ring stage infected in human erythrocytes assessed as growth inhibition after 30 to 50 hrs by microscopic analysis using giemsa staining","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1676005","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5298859,733549,55984,1338440,"=",19.1,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay","F",,,"Plasmodium malariae",5858,,,,,102013,"N",1,"Autocuration",1,,"CHEMBL1690000","ORGANISM","Plasmodium malariae",5858,"Plasmodium malariae",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5298865,733550,55984,1338440,"=",21.7,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay","F",,,"Plasmodium malariae",5858,,,,,102013,"N",1,"Autocuration",1,,"CHEMBL1690001","ORGANISM","Plasmodium malariae",5858,"Plasmodium malariae",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5298874,733552,55984,1338440,"=",4.3,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay","F",,,"Plasmodium ovale",36330,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1690003","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307215,735152,56009,1338547,"=",2.0,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,,"CHEMBL1694200","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307221,735153,56009,1338547,"=",8.0,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,,"CHEMBL1694201","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307230,735151,56009,1338547,"=",5.0,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1694199","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307238,735150,56009,1338547,"=",9.1,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1694198","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307246,735149,56009,1338547,"=",5.7,"nM",1,"IC50",,,"Antimalarial activity against ring stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1694197","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307254,735148,56009,1338547,"=",9.6,"nM",1,"IC50",,,"Antimalarial activity against trophozoites stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,,"CHEMBL1694196","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307262,735147,56009,1338547,"=",10.1,"nM",1,"IC50",,,"Antimalarial activity against ring stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1694195","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5307270,735146,56009,1338547,"=",21.1,"nM",1,"IC50",,,"Antimalarial activity against trophozoites stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum","F",,,"Plasmodium vivax",5855,,,,,102015,"N",1,"Autocuration",1,,"CHEMBL1694194","ORGANISM","Plasmodium vivax",5855,"Plasmodium vivax",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5315772,736762,56108,1339580,,,,1,"Phospholipidosis","Positive",,"Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset","A",,,,,,,,,103779,"N",1,"Autocuration",1,,"CHEMBL1697691","PHENOTYPE","Phospholipidosis",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5317091,736784,56111,1340914,,,,1,"Hepatotoxicity","drug-induced liver injury reported",,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans","A",,,"Homo sapiens",9606,,,,,103956,"N",1,"Autocuration",1,,"CHEMBL1697778","PHENOTYPE","Hepatotoxicity",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5318042,736785,56111,1340914,,,,1,"Hepatotoxicity","drug-induced liver injury reported",,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents","A",,,"Rodentia",9989,,,,,103956,"N",1,"Autocuration",1,,"CHEMBL1697779","PHENOTYPE","Hepatotoxicity",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5318993,736786,56111,1340914,,,,1,"Hepatotoxicity","no drug-induced liver injury reported",,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents","A",,,,,,,,,103956,"N",1,"Autocuration",1,,"CHEMBL1697780","PHENOTYPE","Hepatotoxicity",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5328741,736802,56126,1342319,,,,1,"Phospholipidosis","Positive: weak inducer based on presence of foamy macrophages and cytoplasmic vacuolations",,"Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset","A",,,,,,,,,103779,"N",1,"Autocuration",1,,"CHEMBL1697855","PHENOTYPE","Phospholipidosis",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5420064,737190,51887,1250878,,29092.9,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504444]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"504648","CHEMBL1737994","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",5644445,737137,51887,1250878,,8912.5,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485345, AID485355]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"493014","CHEMBL1737902","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6074395,738262,56167,1394142,,,,0,"Activity","Substrate",,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2C8","A",,,"Homo sapiens",9606,,,,,10163,"D",9,"Expert",1,"4","CHEMBL1743268","SINGLE PROTEIN","Cytochrome P450 2C8",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6178896,744682,57421,1419373,"=",12.0,"nM",1,"IC50",,,"Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 assessed as inhibition of parasite LDH activity after 72 hrs by spectrophotometry","F",,,"Plasmodium falciparum D10",478861,,,,,22226,"U",0,"Autocuration",1,"368275","CHEMBL1772703","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6178897,744683,57421,1419373,"=",16.0,"nM",1,"IC50",,,"Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite LDH activity after 72 hrs by spectrophotometry","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",1,"368276","CHEMBL1772704","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6178941,744684,57421,1419373,,,,0,"EC50","Not Active",,"Vasodilatory activity in pre-contracted Wistar rat aortic rings","F",,,"Rattus norvegicus",10116,,,,,50597,"N",1,"Autocuration",1,"368277","CHEMBL1772705","ORGANISM","Rattus norvegicus",10116,"Rattus norvegicus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6178942,744685,57421,1419373,,,,0,"EC50","Not Active",,"Vasodilatory activity in pre-contracted Wistar rat aortic rings in presence of 1 uM ODQ","F",,,"Rattus norvegicus",10116,,,,,50597,"N",1,"Autocuration",1,"368278","CHEMBL1772706","ORGANISM","Rattus norvegicus",10116,"Rattus norvegicus",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6178947,744694,57421,1419373,,,,0,"Activity","Active",,"Antiplasmodial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as reduction in parasitemia at 1 mg, ip daily for 5 days measured after 72 hrs relative to control","F",,,"Plasmodium berghei str. ANKA",5823,,,,,22226,"U",0,"Autocuration",1,"373927","CHEMBL1772715","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6667156,752407,51887,1250878,,2.9,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504834","CHEMBL1794345","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",6755640,752471,51887,1250878,,16360.1,"nM",1,"Potency","inactive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"540253","CHEMBL1794461","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7239923,752594,51887,1250878,,446.7,"nM",1,"Potency","inactive",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860]","F",,"confirmatory",,,,,,,103691,"D",9,"Autocuration",7,"588855","CHEMBL1794584","SINGLE PROTEIN","Mothers against decapentaplegic homolog 3",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7257403,752590,51887,1250878,,16.5,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7840123,774800,59327,1541663,"=",1.0,,0,"DILI positive/negative","Source: O'brien dataset; Commonality: consistence",,"Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data","A",,,,,,,,,103956,"N",1,"Autocuration",1,"16","CHEMBL1909322","PHENOTYPE","Hepatotoxicity",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7962552,793813,60553,1566082,"=",15.9,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum PH3 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum",5833,"PH3",,,,50425,"N",1,"Autocuration",1,"422099","CHEMBL1932728","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7962567,793814,60553,1566082,"=",4.9,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum 3D7",36329,,,,,22226,"U",0,"Autocuration",1,"422100","CHEMBL1932729","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7962582,793815,60553,1566082,"=",9.1,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum Dd2 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum Dd2",57267,,,,,22226,"U",0,"Autocuration",1,"422101","CHEMBL1932730","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7962597,793816,60553,1566082,"=",7.5,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum TM6 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum",5833,"TM6",,,,50425,"N",1,"Autocuration",1,"422102","CHEMBL1932731","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7962612,793817,60553,1566082,"=",21.2,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,"422103","CHEMBL1932732","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7963866,793818,60553,1566082,"=",15.2,"nM",1,"IC50",,,"Antimalarial activity against Plasmodium falciparum TM4 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum",5833,"TM4",,,,50425,"N",1,"Autocuration",1,"422104","CHEMBL1932733","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",7963881,793819,60553,1566082,"=",8.7,"nM",1,"IC50",,,"Antimalarial activity against chloroquine-resistant Plasmodium falciparum VS/1 infected in human A positive erythrocytes assessed as inhibition of [G-3H]-hypoxanthine uptake after 24 hrs by liquid scintillation counting","F",,,"Plasmodium falciparum VS/1",478864,,,,,22226,"U",0,"Autocuration",1,"422105","CHEMBL1932734","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10955082,829172,62630,1655565,"=",19.0,"nM",1,"Ki",,,"Inhibition of histamine N-methyltransferase by radiochemical assay","B",,,"Homo sapiens",9606,,,,,11327,"H",8,"Autocuration",1,"461118","CHEMBL2059994","SINGLE PROTEIN","Histamine N-methyltransferase",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10955083,829173,62630,1655565,"=",1350000.0,"nM",1,"IC50",,"Outside typical range","Inhibition of Plasmodium falciparum phosphoethanolamine methyltransferase using phospethanolamine as substrate by radiochemical assay in presence of S-adenosylmethionine","B",,,"Plasmodium falciparum",5833,,,,,104572,"D",9,"Autocuration",1,"461117","CHEMBL2059995","SINGLE PROTEIN","Phosphoethanolamine N-methyltransferase",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10955084,829171,62630,1655565,"=",3000000.0,"nM",1,"IC50",,"Outside typical range","Inhibition of Haemonchus contortus phosphoethanolamine methyltransferase1-mediated conversion of phosphoethanolamine to phosphomonomethylethanolamine by radiochemical assay in presence of S-adenosylmethionine","B",,,"Haemonchus contortus",6289,,,,,22226,"U",0,"Autocuration",1,"461119","CHEMBL2059993","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10955085,829170,62630,1655565,"=",3000000.0,"nM",1,"IC50",,"Outside typical range","Inhibition of Haemonchus contortus phosphoethanolamine methyltransferase2 conversion of phosphomonomethylethanolamine to phosphodimethylethanolamine by radiochemical assay in presence of S-adenosylmethionine","B",,,"Haemonchus contortus",6289,,,,,22226,"U",0,"Autocuration",1,"461120","CHEMBL2059992","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10960242,830466,62598,1655441,"=",5.0,"nM",1,"IC50",,,"Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by Geimsa staining","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",1,"460061","CHEMBL2061191","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10960256,830467,62598,1655441,"=",8.0,"nM",1,"IC50",,,"Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as [3H]hypoxanthine incorporation after 24 hrs by scintillation counting","F",,,"Plasmodium falciparum K1",5839,,,,,50426,"N",1,"Autocuration",1,"460062","CHEMBL2061192","ORGANISM","Plasmodium falciparum (isolate K1 / Thailand)",5839,"Plasmodium falciparum K1",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963806,829110,62713,1657941,"=",13.8,"10'-4/M",0,"Ka",,,"Binding affinity to human serum albumin assessed as modified Stern-Volmer association constant at pH 7.4 and 291K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459252","CHEMBL2059932","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963807,829111,62713,1657941,"=",8.39,"10'-4/M",0,"Ka",,,"Binding affinity to human serum albumin assessed as modified Stern-Volmer association constant at pH 7.4 and 301K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459253","CHEMBL2059933","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963808,829112,62713,1657941,"=",4.59,"10'-4/M",0,"Ka",,,"Binding affinity to human serum albumin assessed as modified Stern-Volmer association constant at pH 7.4 and 310K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459254","CHEMBL2059934","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963809,829113,62713,1657941,"=",3.5,"10'-4/M",0,"Kb",,,"Apparent binding affinity to human serum albumin at pH 7.4 and 291K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459255","CHEMBL2059935","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963810,829114,62713,1657941,"=",4.86,"10'-4/M",0,"Kb",,,"Apparent binding affinity to human serum albumin at pH 7.4 and 301K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459256","CHEMBL2059936","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963811,829115,62713,1657941,"=",6.73,"10'-4/M",0,"Kb",,,"Apparent binding affinity to human serum albumin at pH 7.4 and 310K by spectrofluorimetrysis","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459257","CHEMBL2059937","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963812,829116,62713,1657941,"=",7.31,"10'-4/M",0,"Ka",,,"Binding affinity to human serum albumin assessed as modified Stern-Volmer association constant at pH 7.4 and 291K by spectrofluorimetry in presence of warfarin","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459258","CHEMBL2059938","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963813,829117,62713,1657941,"=",11.36,"10'-4/M",0,"Ka",,,"Binding affinity to human serum albumin assessed as modified Stern-Volmer association constant at pH 7.4 and 291K by spectrofluorimetry in presence of ibuprofen","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459259","CHEMBL2059939","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963814,829118,62713,1657941,,,,0,"Activity","Active",,"Induction of conformational changes in human serum albumin assessed as decrease in absorbance at pH 7.4 and 291K by UV-Vis absorption spectrophotometric analysis","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"459260","CHEMBL2059940","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963815,829119,62713,1657941,"=",7.66,"10'-4/M",0,"KSV",,,"Binding affinity to human serum albumin assessed as Stern-Volmer association constant at pH 7.4 and 291K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"461555","CHEMBL2059941","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963816,829120,62713,1657941,"=",5.62,"10'-4/M",0,"KSV",,,"Binding affinity to human serum albumin assessed as Stern-Volmer association constant at pH 7.4 and 301K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"461556","CHEMBL2059942","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10963817,829121,62713,1657941,"=",4.84,"10'-4/M",0,"KSV",,,"Binding affinity to human serum albumin assessed as Stern-Volmer association constant at pH 7.4 and 310K by spectrofluorimetry","A",,,"Homo sapiens",9606,,,,,10697,"D",9,"Autocuration",1,"461557","CHEMBL2059943","SINGLE PROTEIN","Serum albumin",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10983227,835855,63068,1663280,,,,1,"Inhibition","Not Determined",,"Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins","A",,,"Homo sapiens",9606,,,,,17045,"D",9,"Autocuration",1,"467798","CHEMBL2071966","SINGLE PROTEIN","Cytochrome P450 3A4",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10984059,835854,63068,1663280,,,,1,"Inhibition","Not Determined",,"Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins","A",,,"Homo sapiens",9606,,,,,11365,"D",9,"Autocuration",1,"467797","CHEMBL2071965","SINGLE PROTEIN","Cytochrome P450 2D6",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10984280,835853,63068,1663280,,,,1,"Inhibition","Not Determined",,"Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins","A",,,"Homo sapiens",9606,,,,,12912,"D",9,"Autocuration",1,"467796","CHEMBL2071964","SINGLE PROTEIN","Cytochrome P450 2C19",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10985103,835852,63068,1663280,,,,1,"Inhibition","Not Determined",,"Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins","A",,,"Homo sapiens",9606,,,,,12911,"D",9,"Autocuration",1,"467795","CHEMBL2071963","SINGLE PROTEIN","Cytochrome P450 2C9",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10985919,835851,63068,1663280,,,,1,"Inhibition","Not Determined",,"Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins","A",,,"Homo sapiens",9606,,,,,12594,"D",9,"Autocuration",1,"467794","CHEMBL2071962","SINGLE PROTEIN","Cytochrome P450 1A2",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10995283,835861,63068,1663280,"=",208.0,"pmol",0,"Activity",,,"Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH","A",,,"Homo sapiens",9606,,"Liver",,"Microsomes",22226,"U",0,"Autocuration",1,"467804","CHEMBL2071972","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10995395,835860,63068,1663280,,,,0,"Stabilty","Unstable",,"Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis","A",,,"Homo sapiens",9606,,"Liver",,"Microsomes",22226,"U",0,"Autocuration",1,"467803","CHEMBL2071971","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",10996589,835856,63068,1663280,,,,1,"Inhibition","Not Determined",,"Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins","A",,,"Homo sapiens",9606,,,,,17045,"D",9,"Autocuration",1,"467799","CHEMBL2071967","SINGLE PROTEIN","Cytochrome P450 3A4",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",11574713,845164,51887,1250878,,10000.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS Assay for Inhibitors of Hepatitis C Virus (HCV).   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"651820","CHEMBL2114775","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12089677,860285,65779,1737281,"=",43.4,"%",1,"Inhibition",,,"Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting","A",,,"Homo sapiens",9606,,,"HEK293",,104065,"D",9,"Autocuration",1,"466161","CHEMBL2169431","SINGLE PROTEIN","Solute carrier organic anion transporter family member 2B1",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12090489,860284,65779,1737281,"=",28.2,"%",1,"Inhibition",,,"Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting","A",,,"Homo sapiens",9606,,,"HEK293",,104062,"D",9,"Autocuration",1,"466160","CHEMBL2169430","SINGLE PROTEIN","Solute carrier organic anion transporter family member 1B3",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12091601,860283,65779,1737281,"=",24.2,"%",1,"Inhibition",,,"Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting","A",,,"Homo sapiens",9606,,,"HEK293",,103947,"D",9,"Autocuration",1,"466159","CHEMBL2169429","SINGLE PROTEIN","Solute carrier organic anion transporter family member 1B1",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12109889,865019,65917,1740710,,,,0,"Activity","Not Active",,"Antimalarial activity against Plasmodium berghei NK-65 infected in ICR mouse assessed as host survival at 30 mg/kg, po administered at 72, 96 and 120 hrs post infection measured on day 23 post infection by Thompson test","F",,,"Plasmodium berghei",5821,"NK-65",,,,50473,"N",1,"Autocuration",1,"458821","CHEMBL2176183","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12109890,865018,65917,1740710,"=",60.0,"%",0,"Survival",,,"Antimalarial activity against Plasmodium berghei NK-65 infected in ICR mouse assessed as host survival at 30 mg/kg, po administered at 72, 96 and 120 hrs post infection measured on day 17 post infection by Thompson test","F",,,"Plasmodium berghei",5821,"NK-65",,,,50473,"N",1,"Autocuration",1,"458820","CHEMBL2176182","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12134670,877816,66700,1754640,"=",0.7,,0,"Ratio IC50",,,"Resistant index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum W2 to IC50 for chloroquine-sensitive Plasmodium falciparum D10","F",,,"Plasmodium falciparum",5833,,,,,50425,"N",1,"Autocuration",1,"491159","CHEMBL2187311","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12136487,877817,66700,1754640,"=",19.0,"nM",1,"IC50",,,"Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human RBCs after 72 hrs by parasite lactate dehydrogenase assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",1,"491158","CHEMBL2187312","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12136501,877818,66700,1754640,"=",25.0,"nM",1,"IC50",,,"Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human RBCs after 72 hrs by parasite lactate dehydrogenase assay","F",,,"Plasmodium falciparum D10",478861,,,,,22226,"U",0,"Autocuration",1,"491157","CHEMBL2187313","UNCHECKED","Unchecked",,,,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12714004,950894,72766,1877405,,,,0,"Activity","Active",,"Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by saturation transfer difference analysis","B",,,"Homo sapiens",9606,,,,,11653,"D",9,"Autocuration",1,"563992","CHEMBL2349718","SINGLE PROTEIN","Heparanase",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12714011,950895,72766,1877405,,,,0,"Activity","Active",,"Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by NMR analysis","B",,,"Homo sapiens",9606,,,,,11653,"D",9,"Autocuration",1,"563991","CHEMBL2349719","SINGLE PROTEIN","Heparanase",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",12714032,950896,72766,1877405,"=",52600.0,"nM",1,"Kd",,,"Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by surface plasmon resonance assay","B",,,"Homo sapiens",9606,,,,,11653,"D",9,"Autocuration",1,"563990","CHEMBL2349720","SINGLE PROTEIN","Heparanase",9606,"Homo sapiens",,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3035373,600888,49165,864306,"=",7.3,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3037377,600887,49165,864306,"=",8670.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3039554,600886,49165,864306,"=",106.5,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3040815,600885,49165,864306,"=",212.5,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3047315,600890,49166,870542,,7389.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3050806,600889,49166,870542,,1307.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237269,726822,55744,1335104,"=",92.93,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686422","CELL-LINE","HT-29",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237287,726823,55744,1335104,"=",89.28,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686423","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237305,726824,55744,1335104,"=",92.33,"%",1,"Inhibition",,,"Anticancer activity against human SKOV3 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",1,,"CHEMBL1686424","CELL-LINE","SK-OV-3",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237333,726826,55744,1335104,"=",21300.0,"nM",1,"IC50",,,"Anticancer activity against human DU145 cells by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686426","CELL-LINE","DU-145",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237351,726827,55744,1335104,"=",13400.0,"nM",1,"IC50",,,"Anticancer activity against human HT-29 cells by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686427","CELL-LINE","HT-29",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237379,726831,55744,1335104,"=",52.21,"%",1,"Inhibition",,,"Anticancer activity against human DU145 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686431","CELL-LINE","DU-145",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237387,726832,55744,1335104,"=",80.65,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686432","CELL-LINE","HT-29",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237395,726919,55744,1335104,"=",81.16,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686708","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",6233932,752282,57966,1431952,,,,0,"Activity","Active",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",6234102,752283,57966,1431952,"=",305.4,"nM",1,"IC50",,,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",6234735,752283,57966,1431952,"=",29.96,"um",0,"Schizont size","47.83 pixels",,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10879426,817943,61889,1640633,"=",1007.03,"nM",1,"IC50",,,"MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro.","F","In vitro",,"Leishmania infantum",5671,"MHOM/MA/BE/67",,,,50417,"N",1,"Autocuration",17,"8","CHEMBL2028076","ORGANISM","Leishmania infantum",5671,"Leishmania infantum",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10879826,817944,61889,1640633,"=",12381.69,"nM",1,"IC50",,,"MMV: Cytotoxicity against human fibroblasts (MRC-5) cells.","F","In vitro",,"Homo Sapiens",9606,,,"MRC5",,80291,"N",1,"Autocuration",17,"9","CHEMBL2028077","CELL-LINE","MRC5",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10880723,817938,61889,1640633,"=",589.0,"nM",1,"EC50",,,"MMV: Inhibition of Plasmodium falciparum 3D7 (EC50).","F","In vitro",,"Plasmodium Falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",17,"3","CHEMBL2028071","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10881048,817940,61889,1640633,"=",3551.85,"nM",1,"IC50",,,"MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro).","F","In vitro",,"Trypanosoma cruzi",5693,"Tulahuen C4 (LacZ)",,,,50466,"N",1,"Autocuration",17,"5","CHEMBL2028073","ORGANISM","Trypanosoma cruzi",5693,"Trypanosoma cruzi",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10881448,817941,61889,1640633,"=",3836.42,"nM",1,"IC50",,,"MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro).","F","In vitro",,"Trypanosoma brucei brucei",5702,"Squib 427",,,,50420,"N",1,"Autocuration",17,"6","CHEMBL2028074","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10881848,817942,61889,1640633,"=",4028.1,"nM",1,"IC50",,,"MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro).","F","In vitro",,"Trypanosoma brucei rhodesiense",31286,"STIB 900",,,,50725,"N",1,"Autocuration",17,"7","CHEMBL2028075","ORGANISM","Trypanosoma brucei rhodesiense",31286,"Trypanosoma brucei rhodesiense",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031230,842692,65069,1677889,"=",48700.0,"nM",1,"MIC90",,,"MMV: CRC and MIC90 against Mtb (nonreplicating)","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"3","CHEMBL2094263","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031285,842693,65069,1677889,"=",7330.0,"nM",1,"MIC90",,,"MMV: CRC and MIC90 against Mtb (replicating)","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"4","CHEMBL2094264","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031342,842694,65069,1677889,"=",2.59,"uM",0,"LD50",,,"MMV: Cytotoxicity CRC and LD50 against HepG2","F","In vitro",,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",17,"5","CHEMBL2094265","CELL-LINE","HepG2",9606,"Homo sapiens",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031581,842690,65069,1677889,"=",53.9,"%",1,"Inhibition",,,"MMV: Screen against Mtb, single point, nonreplicating, at 25uM","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"1","CHEMBL2094261","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031980,842691,65069,1677889,"=",98.0,"%",1,"Inhibition",,,"MMV: Screen against Mtb, single point, replicating, at 25uM","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"2","CHEMBL2094262","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13200581,954364,72898,1877950,"=",2.0,,0,"Toxicity","Round, overactive",,"MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 24 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"1","CHEMBL2363023","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13200981,954365,72898,1877950,"=",4.0,,0,"Toxicity","Round, degenerate, slow",,"MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 48 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"2","CHEMBL2363024","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201381,954366,72898,1877950,"=",4.0,,0,"Toxicity","Dead",,"MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 72 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"3","CHEMBL2363025","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201595,954367,72898,1877950,"=",0.0,,0,"Toxicity","No effect",,"MMV: Toxicity @ 5 uM to 4-5  Schistosoma mansoni adult males  after 24 h on a scale of 0 (none) - 4 (most).  Includes short descriptors of effects as judged visually (PMID:19597541). Only those Malaria box 'drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"4","CHEMBL2363026","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201636,954368,72898,1877950,"=",0.0,,0,"Toxicity","No effect",,"MMV: Toxicity @ 5 uM to 4-5  Schistosoma mansoni adult males  after 48 h on a scale of 0 (none) - 4 (most).  Includes short descriptors of effects as judged visually (PMID:19597541). Only those Malaria box 'drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"5","CHEMBL2363027","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201676,954369,72898,1877950,"=",0.0,,0,"Toxicity","No effect",,"MMV: Toxicity @ 5 uM to 4-5  Schistosoma mansoni adult males  after 72 h on a scale of 0 (none) - 4 (most).  Includes short descriptors of effects as judged visually (PMID:19597541). Only those Malaria box 'drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"6","CHEMBL2363028","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201716,954370,72898,1877950,"=",100.0,,0,"Motility","No effect",,"MMV: Motility assay. Percent change (relative to DMSO controls) @ 5 uM of  movement of 4-5  Schistosoma mansoni adult males  after 24 h as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493).  Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'.  In these cases the 'toxicity score' should be prioritized.   Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"7","CHEMBL2363029","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201757,954371,72898,1877950,"=",105.7,,0,"Motility","No effect",,"MMV: Motility assay. Percent change (relative to DMSO controls) @ 5 uM of  movement of 4-5  Schistosoma mansoni adult males  after 48 h as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493).  Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'.  In these cases the 'toxicity score' should be prioritized. Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"8","CHEMBL2363030","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201797,954372,72898,1877950,,,,0,"Motility","No effect",,"MMV: Motility assay. Percent change (relative to DMSO controls) @ 5 uM of  movement of 4-5  Schistosoma mansoni adult males  after 72 h as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493).  Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'.  In these cases the 'toxicity score' should be prioritized. Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,22226,"U",0,"Autocuration",17,"9","CHEMBL2363031","UNCHECKED","Unchecked",,,,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2815378,586268,48285,835982,"=",0.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054502","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2828052,586269,48285,835982,"=",191.91,"nM",1,"XC50",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054503","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2828497,586266,48285,835982,"=",95.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054500","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2832813,586270,48285,835982,"=",6.0,"%",1,"Inhibition",,,"GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.","F",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",2,,"CHEMBL1054504","CELL-LINE","HepG2",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2836441,586271,48285,835982,"=",0.93,"%",1,"IFI",,,"GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested","F",,,,,,,,,22226,"U",0,"Autocuration",2,,"CHEMBL1054505","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2851655,586267,48285,835982,"=",97.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054501","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3037765,600888,49165,865311,"=",0.0,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3040147,600887,49165,865311,">",100000.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3042648,600886,49165,865311,"=",541.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3043501,600885,49165,865311,"=",621.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3048222,600890,49166,870165,">",15000.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3051713,600889,49166,870165,,85.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4051814,688739,51887,1064702,"=",25118.9,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding.   (Class of assay: confirmatory) [Related pubchem assays: 596 ]","B",,"confirmatory","Homo sapiens",9606,,,,,103657,"D",9,"Autocuration",7,"1460","CHEMBL1614421","SINGLE PROTEIN","Microtubule-associated protein tau",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4208633,688239,51887,1211822,"=",29092.9,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells.   (Class of assay: confirmatory) ","F",,"confirmatory","Drosophila",7215,,,,,22226,"U",0,"Autocuration",7,"2685","CHEMBL1614459","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4668621,688267,51887,1064702,"=",631.0,"nM",1,"Potency","Not Active",,"PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent).   (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))]","F",,"confirmatory","Escherichia coli",562,,,,,10027,"H",8,"Intermediate",7,"485294","CHEMBL1614530","SINGLE PROTEIN","Beta-lactamase AmpC",83333,"Escherichia coli K-12",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4822270,688546,51887,1064702,"=",31622.8,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,20053,"D",9,"Autocuration",7,"902","CHEMBL1613992","SINGLE PROTEIN","Cellular tumor antigen p53",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",5435729,737257,51887,1211822,,25929.0,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648]","F",,"confirmatory","Homo sapiens",9606,,,,,103144,"D",9,"Autocuration",7,"504444","CHEMBL1738184","SINGLE PROTEIN","Nuclear factor erythroid 2-related factor 2",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",5877291,737042,51887,1211822,,4107.8,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125]","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"504467","CHEMBL1738588","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",6873728,752509,51887,1064702,,89125.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504856]","F",,"confirmatory",,,,,,,104173,"D",9,"Autocuration",7,"504845","CHEMBL1794499","SINGLE PROTEIN","Regulator of G-protein signaling 4",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",7146987,752590,51887,1211822,,293.6,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",11380366,845074,51887,1211822,,14068.4,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1: Hit Confirmation using MMS Stimulated ELG1.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624249","CHEMBL2114872","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",11424889,845072,51887,1211822,,887.7,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with 5FU Viability.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624250","CHEMBL2114870","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",11724750,845177,51887,1211822,,354.8,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode).   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,11758,"D",9,"Autocuration",7,"624417","CHEMBL2114788","SINGLE PROTEIN","Glucagon-like peptide 1 receptor",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12005206,845241,51887,1211822,,2229.7,"nM",1,"Potency","active",,"PubChem BioAssay. HTS assay for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1: Hit Confirmation.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624248","CHEMBL2114909","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12027133,845261,51887,1211822,,12538.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with Unstimulated Viability Assay.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624252","CHEMBL2114929","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12820421,954272,51887,1064702,,3.66,"uM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12840596,954272,51887,1211822,,7.31,"uM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12848317,954305,51887,1211822,,14.58,"uM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",13053391,954305,51887,1064702,,4.61,"uM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237271,726822,55744,1335106,"=",93.62,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686422","CELL-LINE","HT-29",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237289,726823,55744,1335106,"=",78.71,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686423","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237307,726824,55744,1335106,"=",93.32,"%",1,"Inhibition",,,"Anticancer activity against human SKOV3 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",1,,"CHEMBL1686424","CELL-LINE","SK-OV-3",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237397,726919,55744,1335106,"=",77.62,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686708","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237335,726826,55744,1335106,"=",19650.0,"nM",1,"IC50",,,"Anticancer activity against human DU145 cells by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686426","CELL-LINE","DU-145",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237353,726827,55744,1335106,"=",10060.0,"nM",1,"IC50",,,"Anticancer activity against human HT-29 cells by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686427","CELL-LINE","HT-29",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237381,726831,55744,1335106,"=",53.74,"%",1,"Inhibition",,,"Anticancer activity against human DU145 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686431","CELL-LINE","DU-145",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237389,726832,55744,1335106,"=",77.87,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686432","CELL-LINE","HT-29",9606,"Homo sapiens",,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3026227,600885,49165,869072,"=",183.7,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3033162,600888,49165,869072,"=",0.0,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3035173,600887,49165,869072,"=",10900.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3036938,600886,49165,869072,"=",240.7,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3051893,600890,49166,871048,,3599.7,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3052068,600889,49166,871048,,753.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",6233922,752282,57966,1431942,,,,0,"Activity","Active",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",6234092,752283,57966,1431942,"=",277.6,"nM",1,"IC50",,,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",6234725,752283,57966,1431942,"=",31.73,"um",0,"Schizont size","50.67 pixels",,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
589104,"InChI=1S/C28H31N3O/c32-24(22-31-27-14-6-4-12-25(27)26-13-5-7-15-28(26)31)21-30-19-17-29(18-20-30)16-8-11-23-9-2-1-3-10-23/h1-15,24,32H,16-22H2/b11-8+","OC(CN1CCN(C\C=C\c2ccccc2)CC1)Cn3c4ccccc4c5ccccc35","SJ000127662-2",3047668,600890,49166,869983,,649.7,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,7,490,,"A Active",1.0,0.43,0.41,0.45,1198684,"CHEMBRIDGE","5236683"
589104,"InChI=1S/C28H31N3O/c32-24(22-31-27-14-6-4-12-25(27)26-13-5-7-15-28(26)31)21-30-19-17-29(18-20-30)16-8-11-23-9-2-1-3-10-23/h1-15,24,32H,16-22H2/b11-8+","OC(CN1CCN(C\C=C\c2ccccc2)CC1)Cn3c4ccccc4c5ccccc35","SJ000127662-2",3051159,600889,49166,869983,,1397.2,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,7,490,,"A Active",1.0,0.43,0.41,0.45,1198684,"CHEMBRIDGE","5236683"
588911,"InChI=1S/C24H21ClN2O5S/c1-4-32-23(30)20-13(2)26-24-27(21(20)14-5-8-17(31-3)9-6-14)22(29)19(33-24)12-15-11-16(25)7-10-18(15)28/h5-12,21,28H,4H2,1-3H3/b19-12-","CCOC(=O)C1=C(C)N=C2S\C(=C/c3cc(Cl)ccc3O)\C(=O)N2C1c4ccc(OC)cc4","SJ000154494-3",3047173,600890,49166,869753,">",15000.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,8,,44,"A Active",0.98,0.44,0.36,0.49,25884268,"CHEMBRIDGE","5832039"
588911,"InChI=1S/C24H21ClN2O5S/c1-4-32-23(30)20-13(2)26-24-27(21(20)14-5-8-17(31-3)9-6-14)22(29)19(33-24)12-15-11-16(25)7-10-18(15)28/h5-12,21,28H,4H2,1-3H3/b19-12-","CCOC(=O)C1=C(C)N=C2S\C(=C/c3cc(Cl)ccc3O)\C(=O)N2C1c4ccc(OC)cc4","SJ000154494-3",3052363,600889,49166,869753,">",15000.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,8,,44,"A Active",0.98,0.44,0.36,0.49,25884268,"CHEMBRIDGE","5832039"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048037,600890,49166,870300,,1542.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048412,600891,49166,870300,,1139.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum 3D7","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730081","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048584,600892,49166,870300,,1440.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730641","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048756,600893,49166,870300,,1069.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum V1/S","F",,,"Plasmodium falciparum",5833,"V1/S",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730642","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048928,600894,49166,870300,">",21708.8,"nM",1,"EC50",,,"ST_JUDE: Growth inhibition of to Toxoplasma gondii, in human U-2OS cells, as measured by luciferase.","F",,,"Toxoplasma gondii",383379,"RH",,,,50472,"N",1,"Autocuration",4,,"CHEMBL730643","ORGANISM","Toxoplasma gondii",5811,"Toxoplasma gondii",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049100,600895,49166,870300,,5622.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of Trypanosoma brucei","F",,,"Trypanosoma brucei",5702,"3D7",,,,50418,"N",1,"Autocuration",4,,"CHEMBL730920","ORGANISM","Trypanosoma brucei",5691,"Trypanosoma brucei",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049250,600898,49166,870300,,4766.8,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial hepatocellular carcinoma cells (HepG2)","A",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",4,,"CHEMBL1038864","CELL-LINE","HepG2",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049422,600899,49166,870300,,8666.1,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial embryonic kidney cells (HEK293)","A",,,"Homo sapiens",9606,,,"HEK293",,80936,"N",1,"Autocuration",4,,"CHEMBL1038865","CELL-LINE","HEK293",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049594,600900,49166,870300,,8220.4,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human Burkitt''s lymphoma lymphoblast cells (Raji)","A",,,"Homo sapiens",9606,,,"Raji",,80414,"N",1,"Autocuration",4,,"CHEMBL1038866","CELL-LINE","Raji",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049739,600903,49166,870300,,305.4,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum SB-A6","F",,,"Plasmodium falciparum",5833,"SB-A6",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038869","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049911,600904,49166,870300,,1068.1,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum D10 transfected with yeast DHOD","F",,,"Plasmodium falciparum",5833,"D10",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038870","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050009,600896,49166,870300,,8.8,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using Alamar Blue to measure viability of Leishmania major","F",,,"Leishmania major",5664,,,,,50460,"N",1,"Autocuration",4,,"CHEMBL1038862","ORGANISM","Leishmania major",5664,"Leishmania major",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050181,600897,49166,870300,,8409.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human forskin fibroblast cells (BJ)","A",,,"Homo sapiens",9606,,,"BJ",,80704,"N",1,"Autocuration",4,,"CHEMBL1038863","CELL-LINE","BJ",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050508,600901,49166,870300,,651.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum Dd2","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038867","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050680,600902,49166,870300,">",10176.0,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum W2","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038868","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3051528,600889,49166,870300,,1148.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237270,726822,55744,1335105,"=",92.86,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686422","CELL-LINE","HT-29",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237288,726823,55744,1335105,"=",88.05,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686423","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237306,726824,55744,1335105,"=",91.82,"%",1,"Inhibition",,,"Anticancer activity against human SKOV3 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",1,,"CHEMBL1686424","CELL-LINE","SK-OV-3",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237334,726826,55744,1335105,"=",19170.0,"nM",1,"IC50",,,"Anticancer activity against human DU145 cells by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686426","CELL-LINE","DU-145",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237352,726827,55744,1335105,"=",16470.0,"nM",1,"IC50",,,"Anticancer activity against human HT-29 cells by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686427","CELL-LINE","HT-29",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237380,726831,55744,1335105,"=",57.95,"%",1,"Inhibition",,,"Anticancer activity against human DU145 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686431","CELL-LINE","DU-145",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237388,726832,55744,1335105,"=",83.27,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686432","CELL-LINE","HT-29",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237396,726919,55744,1335105,"=",91.58,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686708","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589864,"InChI=1S/C17H19ClN2O2S/c1-21-15-8-7-12(11-16(15)22-2)9-10-19-17(23)20-14-6-4-3-5-13(14)18/h3-8,11H,9-10H2,1-2H3,(H2,19,20,23)","COc1ccc(CCNC(=S)Nc2ccccc2Cl)cc1OC","SJ000180705-2",3047545,600890,49166,870876,,1358.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,11,589,425,"A Active",1.0,0.59,0.55,0.61,2194279,"CHEMBRIDGE","7202723"
589864,"InChI=1S/C17H19ClN2O2S/c1-21-15-8-7-12(11-16(15)22-2)9-10-19-17(23)20-14-6-4-3-5-13(14)18/h3-8,11H,9-10H2,1-2H3,(H2,19,20,23)","COc1ccc(CCNC(=S)Nc2ccccc2Cl)cc1OC","SJ000180705-2",3051036,600889,49166,870876,,1289.6,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,11,589,425,"A Active",1.0,0.59,0.55,0.61,2194279,"CHEMBRIDGE","7202723"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",6882642,752493,51887,1491577,,39810.7,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623]","F",,"confirmatory",,,,,,,100972,"D",9,"Autocuration",7,"588590","CHEMBL1794483","SINGLE PROTEIN","DNA polymerase iota",9606,"Homo sapiens",,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",6894739,752496,51887,1491577,,39810.7,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1)..   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813]","F",,"confirmatory",,,,,,,100144,"D",9,"Autocuration",7,"588795","CHEMBL1794486","SINGLE PROTEIN","Flap endonuclease 1",9606,"Homo sapiens",,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",6958343,752563,51887,1491577,,7079.5,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860]","F",,"confirmatory","Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",7,"588856","CHEMBL1794553","CELL-LINE","HepG2",9606,"Homo sapiens",,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",7025962,752546,51887,1491577,,50118.7,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Kappa.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588638]","F",,"confirmatory",,,,,,,100932,"D",9,"Autocuration",7,"588579","CHEMBL1794536","SINGLE PROTEIN","DNA polymerase kappa",9606,"Homo sapiens",,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",7250901,752594,51887,1491577,,2511.9,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860]","F",,"confirmatory",,,,,,,103691,"D",9,"Autocuration",7,"588855","CHEMBL1794584","SINGLE PROTEIN","Mothers against decapentaplegic homolog 3",9606,"Homo sapiens",,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",11468172,845105,51887,1491577,,2818.4,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,22226,"U",0,"Autocuration",7,"624263","CHEMBL2114716","UNCHECKED","Unchecked",,,,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",12894732,954272,51887,1491577,,0.1,"uM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",13150197,954305,51887,1491577,,0.0891,"uM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",13162488,954333,51887,1491577,,14.13,"uM",1,"Potency","inactive",,"PubChem BioAssay. qHTS of alpha-syn Inhibitors.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,102780,"D",9,"Autocuration",7,"652106","CHEMBL2354282","SINGLE PROTEIN","Alpha-synuclein",9606,"Homo sapiens",,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2814452,586268,48285,839902,"=",1.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054502","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2817881,586271,48285,839902,"=",4.64,"%",1,"IFI",,,"GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested","F",,,,,,,,,22226,"U",0,"Autocuration",2,,"CHEMBL1054505","UNCHECKED","Unchecked",,,,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2825727,586267,48285,839902,"=",60.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054501","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2847278,586270,48285,839902,"=",42.0,"%",1,"Inhibition",,,"GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.","F",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",2,,"CHEMBL1054504","CELL-LINE","HepG2",9606,"Homo sapiens",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2860384,586269,48285,839902,"=",891.91,"nM",1,"XC50",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054503","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2878772,586266,48285,839902,"=",88.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054500","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3034302,600888,49165,869434,"=",13.43,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3036311,600887,49165,869434,">",10000.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3038093,600886,49165,869434,"=",160.4,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3039346,600885,49165,869434,">",1303.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",6235272,752282,57966,1430581,,,,0,"Activity","Inactive",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3024979,600885,49165,868330,"=",548.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3031897,600888,49165,868330,"=",7.14,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3033912,600887,49165,868330,"=",15600.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3035663,600886,49165,868330,"=",529.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",6232787,752282,57966,1431065,,,,0,"Activity","Inactive",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
589605,"InChI=1S/C17H13ClF6N2O3/c18-10-1-3-11(4-2-10)25-15(27)26-12-5-13(28-8-16(19,20)21)7-14(6-12)29-9-17(22,23)24/h1-7H,8-9H2,(H2,25,26,27)","FC(F)(F)COc1cc(NC(=O)Nc2ccc(Cl)cc2)cc(OCC(F)(F)F)c1","SJ000281068-2",3048252,600890,49166,870572,,465.7,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,16,733,,"A Active",0.99,1.3,1.2,1.5,2941320,"ENAMINE","Z56798855"
589605,"InChI=1S/C17H13ClF6N2O3/c18-10-1-3-11(4-2-10)25-15(27)26-12-5-13(28-8-16(19,20)21)7-14(6-12)29-9-17(22,23)24/h1-7H,8-9H2,(H2,25,26,27)","FC(F)(F)COc1cc(NC(=O)Nc2ccc(Cl)cc2)cc(OCC(F)(F)F)c1","SJ000281068-2",3051743,600889,49166,870572,,1358.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,16,733,,"A Active",0.99,1.3,1.2,1.5,2941320,"ENAMINE","Z56798855"
589547,"InChI=1S/C20H19ClN2O2/c21-16-6-3-15(4-7-16)19(23-10-12-25-13-11-23)17-8-5-14-2-1-9-22-18(14)20(17)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccc(Cl)cc4","SJ000243592-3",3047335,600890,49166,870503,,2971.4,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,18,542,144,"A Active",1.0,2.0,1.9,2.1,2943453,"ENAMINE","Z56174631"
589547,"InChI=1S/C20H19ClN2O2/c21-16-6-3-15(4-7-16)19(23-10-12-25-13-11-23)17-8-5-14-2-1-9-22-18(14)20(17)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccc(Cl)cc4","SJ000243592-3",3050826,600889,49166,870503,,2185.6,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,18,542,144,"A Active",1.0,2.0,1.9,2.1,2943453,"ENAMINE","Z56174631"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",1605716,321687,30155,401749,"=",9120.11,"nM",1,"IC50",,,"Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)","B",,,"Rattus norvegicus",10116,,,,,12832,"H",6,"Expert",1,,"CHEMBL872182","SINGLE PROTEIN","Androgen Receptor",10116,"Rattus norvegicus",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",3048251,600890,49166,870571,,3596.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",3051742,600889,49166,870571,,3953.4,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",6445225,752332,51887,1508549,,6309.6,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule agonists of retinoid X receptor alpha signaling.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,275,"D",9,"Autocuration",7,"588544","CHEMBL1794371","SINGLE PROTEIN","Retinoid X receptor alpha",9606,"Homo sapiens",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",7014953,752570,51887,1508549,,44668.4,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of androgen receptor signaling.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,56,"D",9,"Autocuration",7,"588516","CHEMBL1794560","SINGLE PROTEIN","Androgen Receptor",9606,"Homo sapiens",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",7048653,752552,51887,1508549,,35481.3,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of estrogen receptor alpha signaling.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,19,"D",9,"Autocuration",7,"588513","CHEMBL1794542","SINGLE PROTEIN","Estrogen receptor alpha",9606,"Homo sapiens",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",7224290,752302,51887,1508549,,50118.7,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,133,"D",9,"Autocuration",7,"588536","CHEMBL1794293","SINGLE PROTEIN","Peroxisome proliferator-activated receptor gamma",9606,"Homo sapiens",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",11425253,845092,51887,1508549,,54482.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103144,"D",9,"Autocuration",7,"651741","CHEMBL2114890","SINGLE PROTEIN","Nuclear factor erythroid 2-related factor 2",9606,"Homo sapiens",,19,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",3048068,600890,49166,870353,,486.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",3051559,600889,49166,870353,,1021.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",5621689,737137,51887,1346837,,461.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485345, AID485355]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"493014","CHEMBL1737902","UNCHECKED","Unchecked",,,,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",5771345,737344,51887,1346837,,3162.3,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404]","F",,"confirmatory","Homo sapiens",9606,,,,,102672,"D",9,"Autocuration",7,"504332","CHEMBL1738442","SINGLE PROTEIN","Histone-lysine N-methyltransferase, H3 lysine-9 specific 3",9606,"Homo sapiens",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",5844390,736947,51887,1346837,,89125.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391]","F",,"confirmatory","Homo sapiens",9606,,,,,104016,"D",9,"Autocuration",7,"504333","CHEMBL1738312","SINGLE PROTEIN","Bromodomain adjacent to zinc finger domain protein 2B",9606,"Homo sapiens",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",6471993,752320,51887,1346837,,141253.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"540263","CHEMBL1794359","UNCHECKED","Unchecked",,,,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",6811608,752411,51887,1346837,,89125.1,"nM",1,"Potency","inactive",,"PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962]","F",,"confirmatory",,,,,,,103989,"D",9,"Autocuration",7,"540317","CHEMBL1794401","SINGLE PROTEIN","Chromobox protein homolog 1",9606,"Homo sapiens",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",7087740,752590,51887,1346837,,1471.6,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",7384017,752313,51887,1346837,,8492.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project).   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411]","F",,"confirmatory",,,,,,,101018,"D",9,"Autocuration",7,"588342","CHEMBL1794352","SINGLE PROTEIN","Luciferin 4-monooxygenase",7054,"Photinus pyralis",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",11295371,845045,51887,1346837,,29092.9,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells..   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103711,"D",9,"Autocuration",7,"624296","CHEMBL2114843","SINGLE PROTEIN","Geminin",9606,"Homo sapiens",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",11759063,845177,51887,1346837,,7079.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode).   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,11758,"D",9,"Autocuration",7,"624417","CHEMBL2114788","SINGLE PROTEIN","Glucagon-like peptide 1 receptor",9606,"Homo sapiens",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",11881194,845199,51887,1346837,,11220.2,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,100791,"D",9,"Autocuration",7,"624287","CHEMBL2114810","SINGLE PROTEIN","Guanine nucleotide-binding protein G(s), subunit alpha",9606,"Homo sapiens",,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",13168045,954305,51887,1346837,,29.09,"uM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,,20,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589027,"InChI=1S/C13H9Cl3N2O/c14-8-1-3-11(4-2-8)17-13(19)18-12-6-9(15)5-10(16)7-12/h1-7H,(H2,17,18,19)","Clc1ccc(NC(=O)Nc2cc(Cl)cc(Cl)c2)cc1","SJ000144869-2",3047863,600890,49166,869890,,1632.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,21,946,,"A Active",1.0,3.0,2.9,3.3,2063305,"CHEMBRIDGE","5320781"
589027,"InChI=1S/C13H9Cl3N2O/c14-8-1-3-11(4-2-8)17-13(19)18-12-6-9(15)5-10(16)7-12/h1-7H,(H2,17,18,19)","Clc1ccc(NC(=O)Nc2cc(Cl)cc(Cl)c2)cc1","SJ000144869-2",3051354,600889,49166,869890,,3213.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,21,946,,"A Active",1.0,3.0,2.9,3.3,2063305,"CHEMBRIDGE","5320781"
1369535,"InChI=1S/C22H17F2N3O2/c23-22(24)29-16-9-6-15(7-10-16)19(27-18-5-1-2-12-25-18)17-11-8-14-4-3-13-26-20(14)21(17)28/h1-13,19,22,28H,(H,25,27)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(OC(F)F)cc4","SJ000866779-1",11033943,842698,65070,1679280,">",10420.0,"nM",1,"IC50",,,"DNDI: Inhibition of Human African Trypanosomiasis (HAT), STIB 795, in vitro","F","In vitro",,"Trypanosoma brucei brucei",5702,"STIB 795",,,,50420,"N",1,"Autocuration",14,"1007605","CHEMBL2095144","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",,22,,456,"A Active",0.98,3.2,2.7,3.9,2936350,"ENAMINE","Z56794778"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",3047617,600890,49166,870967,,5592.3,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,23,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",3051108,600889,49166,870967,,3759.2,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,23,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",11033739,842698,65070,1679141,"=",4020.0,"nM",1,"IC50",,,"DNDI: Inhibition of Human African Trypanosomiasis (HAT), STIB 795, in vitro","F","In vitro",,"Trypanosoma brucei brucei",5702,"STIB 795",,,,50420,"N",1,"Autocuration",14,"1007605","CHEMBL2095144","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",,23,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",11033740,842697,65070,1679141,">",41670.0,"nM",1,"IC50",,,"DNDI: Cytotoxicity against human MRC-5 lung fibroblast cells.","F","In vitro",,"Homo sapiens",9606,,,"MRC-5 cells",,22226,"U",0,"Autocuration",14,"1002458","CHEMBL2095143","UNCHECKED","Unchecked",,,,23,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3629276,688416,51887,1219954,"=",6511.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus.   (Class of assay: confirmatory) [Related pubchem assays: 1900 (Counter Screen), 1677 (Project Summary), 1902 (Retest at Dose), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus",1301,,,,,50024,"N",1,"Autocuration",7,"1915","CHEMBL1614538","ORGANISM","Streptococcus",1301,"Streptococcus",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3694989,688469,51887,1219954,"=",10512.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of Luciferase Translation or Activity in H4 Neuroglioblastoma Cells.   (Class of assay: confirmatory) [Related pubchem assays: 1813 (Primary HTS), 1827 (Project Summary)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1990","CHEMBL1613869","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3771747,688537,51887,1219954,"=",558.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus.   (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus",1301,,,,,50775,"N",1,"Autocuration",7,"1900","CHEMBL1613983","ORGANISM","Streptococcus sp. 'group A'",36470,"Streptococcus sp. 'group A'",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3830184,688810,51887,1219954,"=",3288.5,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Modulators of miRNAs and/or Activators of miR-21.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103763,"M",3,"Autocuration",7,"2288","CHEMBL1613836","NUCLEIC-ACID","microRNA 21",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4112376,688759,51887,1219954,"=",891.3,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity.   (Class of assay: confirmatory) ","F",,"confirmatory","Mus musculus",10090,,,,,103664,"D",9,"Autocuration",7,"2546","CHEMBL1614441","SINGLE PROTEIN","Nuclear receptor ROR-gamma",10090,"Mus musculus",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4125408,688233,51887,1219954,"=",6540.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS Screen to Identify Cytotoxic Compounds of NIH3T3 cells..   (Class of assay: confirmatory) [Related pubchem assays: 1885 , 1968 ]","F",,"confirmatory",,,,,"NIH3T3",,22226,"U",0,"Autocuration",7,"2010","CHEMBL1614453","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4128672,688235,51887,1219954,"=",21010.0,"nM",1,"IC50","Active",,"PUBCHEM_BIOASSAY: A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium.   (Class of assay: confirmatory) [Related pubchem assays: 2253 , 1863 , 1981 , 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2401","CHEMBL1614455","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4264864,688239,51887,1219954,"=",18356.4,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells.   (Class of assay: confirmatory) ","F",,"confirmatory","Drosophila",7215,,,,,22226,"U",0,"Autocuration",7,"2685","CHEMBL1614459","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4303810,688118,51887,1219954,"=",30190.0,"nM",1,"IC50","Active",,"PUBCHEM_BIOASSAY: A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen..   (Class of assay: confirmatory) [Related pubchem assays: 2253 , 1863 , 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1981","CHEMBL1614127","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4315166,688128,51887,1219954,"=",631.0,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins.   (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)]","F",,"confirmatory","Schistosoma mansoni",6183,,,,,102962,"D",9,"Autocuration",7,"485364","CHEMBL1614161","SINGLE PROTEIN","Thioredoxin glutathione reductase",6183,"Schistosoma mansoni",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4333126,688131,51887,1219954,"=",666.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Retest of Candida albicans Growth in the Presence of Fluconazole.   (Class of assay: confirmatory) [Related pubchem assays: 2007 (Project Summary), 1979 (Primary HTS)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2467","CHEMBL1614164","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4389601,688186,51887,1219954,"=",2960.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella Typhimurium identified in the primary screen.   (Class of assay: confirmatory) [Related pubchem assays: 1863 , 1981 , 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2253","CHEMBL1614312","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4396093,688141,51887,1219954,"=",44668.4,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase).   (Class of assay: confirmatory) ","F",,"confirmatory","Bacillus subtilis",1423,,,,,103681,"D",9,"Autocuration",7,"1490","CHEMBL1614174","SINGLE PROTEIN","4'-phosphopantetheinyl transferase ffp",1423,"Bacillus subtilis",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4399138,688181,51887,1219954,"=",1316.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of Trypanosoma cruzi Replication..   (Class of assay: confirmatory) [Related pubchem assays: 1885 , 1968 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2044","CHEMBL1614307","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4441301,688157,51887,1219954,"=",6309.6,"nM",1,"Potency","Not Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function.   (Class of assay: confirmatory) ","F",,"confirmatory","Influenza A virus (A/WSN/1933(H1N1))",382835,,,,,103736,"D",9,"Autocuration",7,"2326","CHEMBL1614236","SINGLE PROTEIN","Nonstructural protein 1",382835,"Influenza A virus",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4488955,688170,51887,1219954,"=",39810.7,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics  (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)]","B",,"confirmatory","Equus caballus",9796,,,,,103687,"D",9,"Autocuration",7,"485281","CHEMBL1614249","SINGLE PROTEIN","Ferritin light chain",9796,"Equus caballus",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4686389,688274,51887,1219954,"=",33980.0,"nM",1,"IC50","Active",,"PUBCHEM_BIOASSAY: A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium.   (Class of assay: confirmatory) [Related pubchem assays: 2253 , 1981 , 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1863","CHEMBL1613789","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4884259,688653,51887,1219954,"=",3288.5,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21.   (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103763,"M",3,"Autocuration",7,"2289","CHEMBL1614146","NUCLEIC-ACID","microRNA 21",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4901700,688597,51887,1219954,"=",682.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity.   (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus pyogenes M1 GAS",160490,,,,,103661,"H",8,"Autocuration",7,"1902","CHEMBL1614064","SINGLE PROTEIN","Streptokinase A",301447,"Streptococcus pyogenes serotype M1",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4947467,688620,51887,1219954,"=",398.1,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity.   (Class of assay: confirmatory) ","F",,"confirmatory","Mus musculus",10090,,,,,103664,"D",9,"Autocuration",7,"2551","CHEMBL1614087","SINGLE PROTEIN","Nuclear receptor ROR-gamma",10090,"Mus musculus",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4958254,688648,51887,1219954,">",150000.0,"nM",1,"EC50","Not Active","Outside typical range","PUBCHEM_BIOASSAY: Absorbance Microorganism-Based Dose Response HTS to Identify Inhibitors of Streptokinase Expression.   (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1902 (Retest at Dose), 1900 (Counter Screen), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus pyogenes M1 GAS",160490,,,,,103661,"H",8,"Autocuration",7,"1914","CHEMBL1614141","SINGLE PROTEIN","Streptokinase A",301447,"Streptococcus pyogenes serotype M1",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4964328,688623,51887,1219954,"=",9299.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of 5&apos;UTR Stem-Loop Driven Prion Protein mRNA Translation in H4 Neuroglioblastoma Cells.   (Class of assay: confirmatory) [Related pubchem assays: 1827 (Project Summary), 1813 (Primary HTS)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1994","CHEMBL1614090","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4982303,688644,51887,1219954,"=",8866.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Confirmation HTS to Identify Inhibitors of of 5&apos;UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells.   (Class of assay: confirmatory) [Related pubchem assays: 1827 (Project Summary), 1813 (Primary HTS)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1988","CHEMBL1614137","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5345146,737185,51887,1219954,,28183.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845]","F",,"confirmatory","Homo sapiens",9606,,,,,10733,"D",9,"Autocuration",7,"2101","CHEMBL1613818","SINGLE PROTEIN","Beta-glucocerebrosidase",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5556965,737623,51887,1219954,,31622.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709]","F",,"confirmatory","Homo sapiens",9606,,,,,20053,"D",9,"Autocuration",7,"504706","CHEMBL1738132","SINGLE PROTEIN","Cellular tumor antigen p53",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5618250,737137,51887,1219954,,35481.3,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485345, AID485355]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"493014","CHEMBL1737902","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5692514,737298,51887,1219954,">",118576.0,"nM",1,"IC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Absorbance-based bacterial cell-based high throughput dose response assay for inhibitors of AddAB recombination protein complex.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435030, AID449728, AID449731, AID488942, AID488955, AID488956]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"492959","CHEMBL1738325","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5740966,737344,51887,1219954,,11220.2,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404]","F",,"confirmatory","Homo sapiens",9606,,,,,102672,"D",9,"Autocuration",7,"504332","CHEMBL1738442","SINGLE PROTEIN","Histone-lysine N-methyltransferase, H3 lysine-9 specific 3",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5791231,737425,51887,1219954,"=",105490.0,"nM",1,"IC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput dose response assay for inhibitors of bacterial viability.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435030, AID449728, AID449731, AID488942, AID488955, AID488956]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"492958","CHEMBL1738643","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5821301,736947,51887,1219954,,39810.7,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391]","F",,"confirmatory","Homo sapiens",9606,,,,,104016,"D",9,"Autocuration",7,"504333","CHEMBL1738312","SINGLE PROTEIN","Bromodomain adjacent to zinc finger domain protein 2B",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5921021,737042,51887,1219954,,16353.5,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125]","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"504467","CHEMBL1738588","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5978668,737110,51887,1219954,">",118576.0,"nM",1,"IC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput dose response assay to identify inhibitors of RecBCD.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435030, AID449728, AID449731, AID488942, AID488955, AID488956]","F",,"confirmatory","Escherichia coli str. K-12 substr. MG1655",511145,,,,,104804,"H",6,"Autocuration",7,"492957","CHEMBL1737858","PROTEIN COMPLEX","Exodeoxyribonuclease V",83333,"Escherichia coli (strain K12)",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6432176,688444,51887,1219954,"=",787.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Secondary Assay to Identify Inhibitors of Resistant C. albicans Growth in the Presence of Fluconazole.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007]","F",,"confirmatory",,,,,,,103684,"H",8,"Autocuration",7,"2423","CHEMBL1613820","SINGLE PROTEIN","ATP-dependent molecular chaperone HSP82",294748,"Candida albicans (strain WO-1) (Yeast)",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6555241,752386,51887,1219954,"=",11900.0,"nM",1,"AC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Free Homogeneous Secondary Screen to Identify Inhibitors of DnaB-Intein Splicing Activity.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2223, AID489010, AID492950]","F",,"confirmatory",,,,,,,103988,"H",8,"Autocuration",7,"449749","CHEMBL1794324","SINGLE PROTEIN","Replicative DNA helicase",1773,"Mycobacterium tuberculosis",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6698547,752407,51887,1219954,,3696.4,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504834","CHEMBL1794345","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6773009,752436,51887,1219954,"=",932.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Free Homogeneous Dose Retest to Identify Inhibitors of RecA-Intein Splicing Activity.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2097, AID2223, AID489010, AID492950]","F",,"confirmatory",,,,,,,103967,"H",8,"Autocuration",7,"435010","CHEMBL1794426","SINGLE PROTEIN","Protein RecA",1773,"Mycobacterium tuberculosis",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6773335,688696,51887,1219954,"=",2447.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Secondary Assay to Measure Toxicity of Compounds Not in the Presence of Fluconazole.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007, AID434946]","F",,"confirmatory",,,,,,,103684,"H",8,"Autocuration",7,"2387","CHEMBL1614288","SINGLE PROTEIN","ATP-dependent molecular chaperone HSP82",294748,"Candida albicans (strain WO-1) (Yeast)",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6847600,752506,51887,1219954,"=",3178.0,"nM",1,"AC50","active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Retest to Confirm Inhibitors of  Beta Cell Apoptosis.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435005, AID435007]","F",,"confirmatory",,,,,"INS1",,80764,"N",1,"Autocuration",7,"449756","CHEMBL1794496","CELL-LINE","INS1",10116,"Rattus norvegicus",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7001352,752581,51887,1219954,"=",6721.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Secondary Assay to Identify Inhibitors of Hsp90.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007, AID434938]","F",,"confirmatory",,,,,,,103684,"H",8,"Autocuration",7,"2400","CHEMBL1794571","SINGLE PROTEIN","ATP-dependent molecular chaperone HSP82",294748,"Candida albicans (strain WO-1) (Yeast)",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7056217,688210,51887,1219954,">",180000.0,"nM",1,"EC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Luminescence Cell-Based Secondary Assay to Identify Inhibitors of Calcineurin.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007]","F",,"confirmatory",,,,,,,103704,"D",9,"Autocuration",7,"2388","CHEMBL1614385","SINGLE PROTEIN","Serine/threonine-protein phosphatase",573826,"Candida dubliniensis (strain CD36 / CBS 7987 / NCPF 3949 / NRRLY-17841) (Yeast)",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7123514,752590,51887,1219954,,13115.4,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7330078,688279,51887,1219954,"=",10912.0,"nM",1,"EC50","inconclusive",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Secondary Assay for toxicity in mammalian fibroblasts.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2327","CHEMBL1613794","UNCHECKED","Unchecked",,,,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7391871,752310,51887,1219954,">",380000.0,"nM",1,"AC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Fluorescence Cell-Free Homogeneous Secondary Screen to Identify Non-Covalent Inhibitors of RecA-Intein Splicing Activity.   (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2223, AID489010, AID492950]","F",,"confirmatory",,,,,,,103988,"H",8,"Autocuration",7,"449750","CHEMBL1794349","SINGLE PROTEIN","Replicative DNA helicase",1773,"Mycobacterium tuberculosis",,24,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3034207,600888,49165,869339,"=",4.35,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3036216,600887,49165,869339,">",22840.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3037998,600886,49165,869339,"=",400.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3039251,600885,49165,869339,"=",267.2,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",6233758,752283,57966,1431901,"=",146.7,"nM",1,"IC50",,,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",6233881,752282,57966,1431901,,,,0,"Activity","Active",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",6234684,752283,57966,1431901,"=",16.28,"um",0,"Schizont size","26.00 pixels",,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,25,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3037611,600888,49165,865157,"=",7.69,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3039993,600887,49165,865157,">",61220.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","A",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3041414,600886,49165,865157,"=",405.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3042563,600885,49165,865157,"=",365.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3046975,600890,49166,871145,,3029.8,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3052165,600889,49166,871145,,2998.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",6236452,752282,57966,1434393,,,,0,"Activity","Inactive",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",,26,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
589478,"InChI=1S/C26H25N3O2/c30-26-22(14-13-18-8-6-16-28-25(18)26)24(29-23-12-3-4-15-27-23)19-7-5-11-21(17-19)31-20-9-1-2-10-20/h3-8,11-17,20,24,30H,1-2,9-10H2,(H,27,29)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(OC5CCCC5)c4","SJ000137729-2",3047274,600890,49166,870420,,4159.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,28,913,128,"B Active",1.0,9.0,6.8,9.2,2007839,"CHEMBRIDGE","7925786"
589478,"InChI=1S/C26H25N3O2/c30-26-22(14-13-18-8-6-16-28-25(18)26)24(29-23-12-3-4-15-27-23)19-7-5-11-21(17-19)31-20-9-1-2-10-20/h3-8,11-17,20,24,30H,1-2,9-10H2,(H,27,29)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(OC5CCCC5)c4","SJ000137729-2",3050765,600889,49166,870420,,3714.4,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",,28,913,128,"B Active",1.0,9.0,6.8,9.2,2007839,"CHEMBRIDGE","7925786"
1369300,"InChI=1S/C20H19ClN2O2/c21-17-6-2-1-5-15(17)19(23-10-12-25-13-11-23)16-8-7-14-4-3-9-22-18(14)20(16)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccccc4Cl","SJ000866799-1",11033482,842697,65070,1678976,">",20830.0,"nM",1,"IC50",,,"DNDI: Cytotoxicity against human MRC-5 lung fibroblast cells.","F","In vitro",,"Homo sapiens",9606,,,"MRC-5 cells",,22226,"U",0,"Autocuration",14,"1002458","CHEMBL2095143","UNCHECKED","Unchecked",,,,29,989,546,"B Active",0.98,9.5,8.4,10.0,1092384,"ENAMINE","Z56830583"
1369300,"InChI=1S/C20H19ClN2O2/c21-17-6-2-1-5-15(17)19(23-10-12-25-13-11-23)16-8-7-14-4-3-9-22-18(14)20(16)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccccc4Cl","SJ000866799-1",11033483,842698,65070,1678976,"=",5590.0,"nM",1,"IC50",,,"DNDI: Inhibition of Human African Trypanosomiasis (HAT), STIB 795, in vitro","F","In vitro",,"Trypanosoma brucei brucei",5702,"STIB 795",,,,50420,"N",1,"Autocuration",14,"1007605","CHEMBL2095144","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",,29,989,546,"B Active",0.98,9.5,8.4,10.0,1092384,"ENAMINE","Z56830583"
